Cardiac Arrest and Global Ischemia Reperfusion Injury: Role of mitochondria and Cannabinoid Receptor 2 signaling.

Jennifer L. Bradley
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd

Part of the Cardiovascular Diseases Commons, Cardiovascular System Commons, and the Nervous System Commons

© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/6520

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Cardiac Arrest and Global Ischemia Reperfusion Injury: Role of mitochondria and Cannabinoid Receptor 2 signaling.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University

by

Jennifer Leigh Bradley
Master of Science, Virginia Commonwealth University, 2016
Bachelor of Art, Berea College, 2006

Director: Wanchun Tang, MD, MCCM, FAHA, FNAI
Affiliate Professor, Department of Microbiology and Immunology
Professor, Emergency Medicine

Virginia Commonwealth University
Richmond, VA
February, 2021
Acknowledgement

The author wishes to thank several people. I thank Dr. Gail Christie for accepting me to the MBG program for my MS and PhD. She was always available to guide and listen and for that I am truly thankful. I greatly appreciate Dr. Michael McVoy’s mentorship throughout my PhD. He has been invaluable as a mentor for this process and next steps. I would like to thank my advisor, Dr. Wanchun Tang, and the Deputy Directors of the Weil Institute, Dr. Joseph Ornato and Dr. Mary Ann Peberdy, for allowing me to work on my PhD part-time while working as a Research Manager. I am grateful for their guidance and knowledge. I would also like to thank the members of my graduate committee: Dr. Martin Mangino, Dr. Xianjun Fang, Dr. Huiping Zhou and Dr. Gea-Ny Tseng for their time and guidance. Dr. Martin Mangino was always available to answer my questions, to provide a platform for scientific discussion and was instrumental with allowing Jad Khoraki to help me with VF induction for my in vivo studies. Dr. Huiping Zhou and her student, Yanyan Wang, taught me cell culture technique for RAW 264.7 macrophage cells and provided me with a crash course in Prism. Dr. Gea-Ny Tseng and her laboratory members collaborated with the Weil Institute and prepared heart whole tissue lysates for proteomic analysis completed by Poochon Scientific LLC. I am also thankful for our Co-Corresponding author, Dr. Edward Lesnefsky, for providing his laboratory and Jeremy’s time to teach Xianfei Ji and me how to isolate mitochondria, for guiding me through manuscript preparation and review and for completing the ETC assay with the help of his technician Rabiya Shabman. My peers throughout this process have been invaluable in sharing their knowledge, time and technique. I would especially like to thank Apparao Kummarapurugu, Shuo Zheng, Jeremy Thompson, Ria Fyffe-Friel and Jad Khoraki. Karen Lo, a summer medical student volunteer, graciously created the potential role of WIN55 in S100A8/A9 mediated inflammation in IR injury figure. Lastly, I would like to thank my family for enduring all that accompanies a graduate education. My husband and daughter provided encouragement, support and understanding throughout. Many people have supported me during my journey and I am indebted for everyone’s time and support.

Dedicated to family members that have passed on due to heart disease.
Table of Contents

Acknowledgement .................................................................................................................. ii

Table of Contents .................................................................................................................. iii

List of Tables .......................................................................................................................... vi

List of Figures ........................................................................................................................ vii

List of Abbreviations ............................................................................................................ xi

Abstract .................................................................................................................................. xiv

Chapter

1 Introduction and Literature Review .................................................................................... 17

I. Cardiac Arrest ..................................................................................................................... 17

   A. Epidemiology and Disease Spectrum ........................................................................... 17
   B. Ischemia Reperfusion Injury ...................................................................................... 17
   C. Mitochondrial Dysfunction ......................................................................................... 18
   D. Post Cardiac Arrest Syndrome ................................................................................... 22

II. Role of Inflammatory Mediators in Cardiac Arrest .......................................................... 24

   A. Pro-inflammatory mediators (Tumor Necrosis Factor α and interleukin 6) ............ 24
   B. S100A8 and S100A9 ................................................................................................. 27
   C. Anti-inflammatory mediators (interleukin 10) ......................................................... 30

III. Cannabinoids .................................................................................................................. 31

   A. Endocannabinoid System (ECS) ............................................................................. 31
   B. Cannabinoid Receptors ............................................................................................ 33
   C. Anti-inflammatory properties of CB₂ ....................................................................... 38
IV. Research Objectives .......................................................................................................................... 42

2 Materials and Methods .......................................................................................................................... 44

I. Reagents .................................................................................................................................................. 44

II. In vivo-Mitochondria .............................................................................................................................. 44

III. In vivo-Proteomics .................................................................................................................................. 49

IV. In vitro-WIN55 ........................................................................................................................................ 58

V. In vivo-WIN55 .......................................................................................................................................... 58

VI. Statistical Analysis ................................................................................................................................. 63

3 Cerebral and myocardial mitochondrial injury differ in a rat model of cardiac arrest and cardiopulmonary resuscitation ........................................................................................................................................ 64

Rationale ..................................................................................................................................................... 64

Results ........................................................................................................................................................... 64

Discussion .................................................................................................................................................... 78

4 Quantitative mass spectrometric analysis of cardiac whole tissue lysate proteome changes from our rat cardiac arrest and cardiopulmonary resuscitation model ................................................................................................................................. 84

Rationale ..................................................................................................................................................... 84

Results ........................................................................................................................................................... 85

Discussion .................................................................................................................................................... 94

5 Anti-Inflammatory activity of WIN55, 212-2, a non-selective cannabinoid CB1/CB2 receptor agonist in cultured RAW264.7 macrophage cells ................................................................................................................. 97

Rationale ..................................................................................................................................................... 97

Results ........................................................................................................................................................... 98

Discussion .................................................................................................................................................... 102
<table>
<thead>
<tr>
<th>6</th>
<th>One mechanism of anti-inflammatory activity of cannabinoid agonist WIN55, 212-2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>on outcomes of CPR is binding cannabinoid receptor 2 (CB$_2$) ..............</td>
</tr>
</tbody>
</table>

|   | Rationale ........................................................................................................ 104 |
|   | Results ............................................................................................................ 105 |
|   | Discussion ...................................................................................................... 116 |

| 7 | Summary and Future Direction .................................................................. 118 |

|   | References .................................................................................................. 122 |
|   | Vita ............................................................................................................ 141 |
List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1</td>
<td>Summary of 11 cell pellet sample labeling</td>
<td>54</td>
</tr>
<tr>
<td>Table 2</td>
<td>Physiologic parameters</td>
<td>63</td>
</tr>
<tr>
<td>Table 3</td>
<td>Mean Percent Change of Rate of oxidative phosphorylation in brain and heart mitochondria using TMPD as complex IV substrate.</td>
<td>69</td>
</tr>
<tr>
<td>Table 4</td>
<td>Brain and heart mitochondria Electron Transport Chain Results</td>
<td>72</td>
</tr>
</tbody>
</table>
List of Figures

Figure 1. Role of TLR in production of inflammatory mediators ...........................................21
Figure 2. Involvement of S100 proteins in stress and inflammation .........................................28
Figure 3. S100A8/A9 effects through TLR4 .............................................................................30
Figure 4. WIN55 is a full agonist for CB1 and CB2 .................................................................32
Figure 5. Cannabinoid receptor signaling ..................................................................................35
Figure 6. Cross-talk between PPARs and TLRs and NFκβ ........................................................38
Figure 7. Brain CB2 expression and function and association with neuropsychiatric and neurological diseases ................................................................................................................39
Figure 8. Mapping of cannabinoid-sensitive receptors and eCBs in the heart ............................40
Figure 9. Cardiac impact of cannabinoid receptors ....................................................................41
Figure 10. WIN55, 212-2 can be coupled to either CB1 or CB2 with different functional consequences ..............................................................................................................................43
Figure 11. In vivo-Mitochondria Experimental Protocol ............................................................46
Figure 12. Mitochondria Electron Transport Chain Complex substrates and inhibitors ...........48
Figure 13. In vivo-Proteomics Experimental Protocol ...............................................................51
Figure 14. LV Apex Epi ..............................................................................................................52
Figure 15. Poochon Scientific Schematic of Experimental Workflow .......................................56
Figure 16. Poochon Scientific Schematic of Experimental Workflow .......................................57
Figure 17. In vivo-Study Design ...............................................................................................60
Figure 18. In vivo-WIN55 Experimental Protocol ......................................................................61
Figure 19. SR141716A is an antagonist for CB1..........................62
Figure 20. BM oxidative phosphorylation with glutamate as a complex I substrate...........66
Figure 21. SSM oxidative phosphorylation with glutamate as a complex I substrate...........67
Figure 22. IFM oxidative phosphorylation with glutamate as a complex I substrate..........68
Figure 23. BM enzyme activity confirmation of Complex I damage..........................70
Figure 24. BM enzyme activity of NADH:ferricyanide oxidoreductase.......................71
Figure 25. SSM enzyme activity confirmation of Complex I damage..........................73
Figure 26. SSM enzyme activity of NADH:ferricyanide oxidoreductase.......................74
Figure 27. IFM enzyme activity of Complex I..................................................75
Figure 28. BM calcium retention capacity (CRC)..............................................76
Figure 29. SSM calcium retention capacity (CRC)..............................................77
Figure 30. IFM calcium retention capacity (CRC)..............................................78
Figure 31. Supernatant BCA Assay.................................................................86
Figure 32. Volcano Plot 4,997 Proteins Identified by Poochon Scientific......................87
Figure 33. Volcano Plot CPR/Norm+Sham Ratio <0.75 and >1.25.............................87
Figure 34. 3,195 converted Kegg proteins rno00190 Oxidative phosphorylation...........89
Figure 35. 3,195 converted Kegg proteins rno04610 Complement and coagulation cascades....90
Figure 36. 3,195 converted Kegg proteins rno04620 Toll-like receptor signaling pathway......91
Figure 37. 3,195 converted Kegg proteins rno04062 Chemokine signaling pathway...........92
Figure 38. 64 converted Kegg proteins (CPR/Sham+Norm Ratio -log10 p>1.25 ) rno04610 Complement and coagulation cascades..................................................93
Figure 39. REVIGO gene ontology clustering of biological processes based on semantic similarity. 94

Figure 40. Pre-treatment with WIN55 decreased TNFα compared to 6hrs LPS. 99

Figure 41. Pre-treatment with WIN55 decreased IL6 compared to 24hrs LPS. 100

Figure 42. Pre-treatment with WIN55 decreased IL1β compared to 24hrs LPS. 101

Figure 43. Blood temperature was not different between groups. 106

Figure 44. MAP in WIN55 + Hypothermia and WIN55 + Normothermia decreased significantly compared with Normothermia. 107

Figure 45. HR in WIN55 + Hypothermia and WIN55 + Normothermia decreased significantly compared with Normothermia. 107

Figure 46. ETCO₂ in WIN55 + Hypothermia increased significantly compared with Normothermia. 108

Figure 47. HR in SR141716A+WIN55 decreased significantly compared to 2% Tween 80 at ROSC 2hrs and 3hrs. 109

Figure 48. ETCO₂ increased significantly compared with 2% Tween 80 at ROSC 1hr and 4hrs. 110

Figure 49. Significant improvement in myocardial function as measured by CO. 111

Figure 50. Significant improvement in myocardial function as measured by EF. 111

Figure 51. Significant improvement in myocardial function as measured by MPI. 112

Figure 52. MPI in SR141716A+WIN55 increased significantly compared with 2% Tween 80 at ROSC 4hrs. 113
Figure 53. Plasma TNFα.................................................................114
Figure 54. Plasma IL6.................................................................114
Figure 55. Plasma Troponin I......................................................115
Figure 56. Plasma IL10...............................................................115
Figure 57. Plasma S100A8..........................................................116
Figure 58. Pathways of cannabinoid receptor-mediated protection against ischemia reperfusion injury.........................................................120
Figure 59. Potential WIN55 inhibition of S100A8 and S100A9.........................121
List of Abbreviations

μg  microgram
μL  microliter
μm  micrometer
μM  micromolar
2-AG 2-arachidonoylglycerol
AC  adenylate cyclase
ACA asphyxial cardiac arrest
ADP adenosine diphosphate
AEA Arachidonoyl ethanolamide or anandamide
ATP adenosine triphosphate
ANOVA analysis of variance
BBB blood brain barrier
BM brain mitochondria
Breg B regulatory
BSA bovine serum albumin
CA cardiac arrest
CB1 cannabinoid receptor 1
CB2 cannabinoid receptor 2
CBF cerebral blood flow
CO cardiac output
COX cyclooxygenase
COMICA characterization of mitochondrial injury after cardiac arrest
CPP coronary perfusion pressure
CPR cardiopulmonary resuscitation
CRC calcium retention capacity
CypD cycophilin D
DAMPs damage-associated molecular patterns
DMEM Dulbecco’s modified eagle medium
DNA deoxyribonucleic acid
EF ejection fraction
eCB endocannabinoid
ECG electrocardiogram
ECS endocannabinoid system
ETC electron transport chain
ETCO2 end-tidal carbon dioxide
ELISA enzyme-linked immunosorbent assay
FiO2 fraction of inspired oxygen
HR heart rate
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAGE</td>
<td>receptor for advanced glycation end products</td>
</tr>
<tr>
<td>ROSC</td>
<td>return of spontaneous circulation</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>rpm</td>
<td>revolutions per minute</td>
</tr>
<tr>
<td>rRNA</td>
<td>ribosomal ribonucleic acid</td>
</tr>
<tr>
<td>SCA</td>
<td>sudden cardiac arrest</td>
</tr>
<tr>
<td>SCD</td>
<td>sudden cardiac death</td>
</tr>
<tr>
<td>SD</td>
<td>standard deviation</td>
</tr>
<tr>
<td>SDS</td>
<td>sodium dodecyl sulfate</td>
</tr>
<tr>
<td>SSM</td>
<td>subsarcolemmal mitochondria</td>
</tr>
<tr>
<td>TTM</td>
<td>targeted temperature management</td>
</tr>
<tr>
<td>Tregs</td>
<td>regulatory T cells</td>
</tr>
<tr>
<td>TLR</td>
<td>toll-like receptor</td>
</tr>
<tr>
<td>TMB</td>
<td>3,3',5,5'-Tetramethylbenzidine</td>
</tr>
<tr>
<td>TMPD</td>
<td>$N,N',N',N'$ tetramethyl $p$-phenylenediamine</td>
</tr>
<tr>
<td>TNFα</td>
<td>tumor necrosis factor $\alpha$</td>
</tr>
<tr>
<td>TRAF6</td>
<td>TNFR-associated factor 6</td>
</tr>
<tr>
<td>VF</td>
<td>ventricular fibrillation</td>
</tr>
<tr>
<td>VFCA</td>
<td>ventricular fibrillation cardiac arrest</td>
</tr>
<tr>
<td>WIN55</td>
<td>WIN55, 212-2</td>
</tr>
</tbody>
</table>
Abstract

Cardiac Arrest and Global Ischemia Reperfusion Injury: Role of mitochondria and Cannabinoid Receptor 2 signaling.

By Jennifer Leigh Bradley

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2021

Director: Wanchun Tang, MD, MCCM, FAHA, FNAI
Affiliate Professor, Department of Microbiology and Immunology
Professor, Emergency Medicine

Sudden cardiac arrest is a major public health challenge in the United States with very poor outcomes. Current advanced cardiac life support therapies with cardiopulmonary resuscitation, defibrillation, and medications save less than 5% of victims despite substantial evidence that many of these lives could be saved with improved resuscitation protocols including the expanded use of hypothermia. Clinically, no effective treatment other than targeted temperature management is utilized. We have previously demonstrated that WIN55, 212-2 (WIN55), a non-selective cannabinoid CB₁/CB₂ receptor agonist, induced hypothermia when administered immediately following resuscitation with significantly improved post-resuscitation myocardial and cerebral function and duration of survival. We further demonstrated that the hypothermia effect of WIN55 is mediated through CB₁ receptors.

However, the results of our previous studies indicated that the beneficial effect of WIN55 on myocardial and cerebral function and duration of survival may not be solely due to its
hypothermic effect. The overall objective of this study is to determine if cardiac arrest causes mitochondrial dysfunction and increased plasma concentrations of TNFα, IL6 and IL10. Intramuscular Administration of SR141716A (CB₁ antagonist) before ventricular fibrillation + cardiopulmonary resuscitation followed by infusion of WIN55 5 min after return of spontaneous circulation will prohibit the release of inflammatory mediators caused by cardiac arrest via the CB₂ receptor.

We explored the effects of cardiac arrest on mitochondria populations and heart whole tissue lysate proteomics utilizing the Weil Institute’s in vivo rat model of cardiac arrest and cardiopulmonary resuscitation. We have discovered that brain mitochondria are more sensitive to global ischemia compared to heart mitochondria. Additionally, complex I is the most sensitive electron transport chain complex to ischemic injury and is a major control point of the rate of oxidative phosphorylation following cardiac arrest and cardiopulmonary resuscitation. Preservation of brain mitochondrial activity and function during cardiac arrest may enhance outcomes and recovery.

A recent article focusing on acute myocardial infarction was able to link S100A8 and S100A9 gene upregulation during ischemia and reperfusion and revealed this caused mitochondrial dysfunction in cardiomyocytes. S100A8 and S100A9 protein expression levels were upregulated in rat LV Apex epicardium whole tissue lysate from animals that experienced global ischemia reperfusion injury via cardiac arrest and cardiopulmonary resuscitation. Further studies are necessary to confirm S100A8 and S100A9 proteins increase expression in brain and heart tissue samples after cardiac arrest and cardiopulmonary resuscitation.

Testing WIN55 as a possible pharmacologic tool, in vitro results indicated that WIN55 was anti-inflammatory. Therefore, we moved to in vivo studies with intramuscular administration
of SR141716A (CB₁ antagonist) before ventricular fibrillation + cardiopulmonary resuscitation followed by infusion of WIN55 5 min after return of spontaneous circulation. After treatment, plasma concentrations of TNFα, IL6 and IL10 were decreased at return of spontaneous circulation 4hrs. One possible mechanism to drive down proinflammatory cytokine release is binding CB₂. WIN55 could be a novel pharmacologic tool against cardiac arrest as it can induce hypothermia and it has ant-inflammatory effects. Further studies are needed to determine mechanism of action for anti-inflammatory effects as peroxisome proliferator-activated receptors are also cannabinoid targets.
CHAPTER 1: Introduction and Literature Review

I. Cardiac Arrest
   A. Epidemiology and Disease Spectrum
   Cardiac arrest (CA) is a major public health problem with substantial morbidity and mortality. It is the cessation of cardiac mechanical activity, as confirmed by the absence of signs of circulation (1). CA is characterized by severe and generalized ischemia that persists during the resuscitation efforts and reverses only after restoration of spontaneous circulation (ROSC) (2). An operational definition of sudden cardiac arrest (SCA) is unexpected CA that results in attempts to restore circulation (1). If resuscitation attempts are unsuccessful, this situation is referred to as sudden cardiac death (SCD). In the United States, any-mention sudden cardiac death (SCD) mortality in 2017 was 379,133 (1). Over the past 5 decades, the strategy of cardiopulmonary resuscitation (CPR) has been focused on early defibrillation, better and more effective chest compression, and more recently, post-resuscitation management including therapeutic hypothermia. However, the current outcomes of CPR are disappointing, which yield a functional survival rate of only 8.2% (1). Circulatory failure and myocardial dysfunction resulting from CA largely contribute to morbidity and mortality after initially successful CPR (3). Out-of-hospital cardiac arrest (OHCA) is a significant cause of death and disability in adults with 356,461 reported “EMS-worked” cases per year in the United States (1).

B. Ischemia Reperfusion Injury
   Ischemia is an imbalance between the oxygen demand of the tissue and the oxygen delivery that it receives. Oxygen delivery could be simple diffusion or the heart delivering oxygen conductively (oxygen through blood flow). Whenever oxygen delivery does not match demand, technically it is ischemia. Ischemia is a condition where energy expenditure outpaces energy production. For aerobic cells ischemia is a critical change in the oxygen demand to delivery ratio (4). Ischemia Reperfusion (IR) injury is a complex process, which involves several
interrelated factors, including a decrease in cellular adenosine triphosphate (ATP) levels, accumulation of hydrogen ions, calcium overload, and production of reactive oxygen species (ROS) (5). Cerebral and myocardial tissue suffers from IR injury even after successful CPR (6, 7). The destructive effects of IR arise from the acute generation of ROS subsequent to reoxygenation, which inflicts direct tissue damage and initiates a chain of deleterious cellular responses leading to inflammation, cell death, and eventually organ failure (8). The cessation (ischemia) and restoration (reperfusion) of cerebral blood flow (CBF) after CA induce inflammatory processes that can result in additional brain injury (9). Post-cardiac arrest (post-CA) ischemia induces neurodegeneration, cerebral edema and impaired cerebrovascular autoregulation within the brain (10). This phenomenon is reflected in 2004 epidemiological data that shows brain injury as the leading cause of death post-CA, accounting for 68% and 23% of OHCA and in-hospital cardiac arrest (IHCA) deaths (10).

Post-arrest myocardial dysfunction includes the development of low cardiac output (CO) or ventricular systolic or diastolic dysfunction (7). The pathophysiology involves cardiovascular IR injury and cardiovascular toxicity from excessive levels of inflammatory cytokine activation, among other contributing factors (7). There is an almost instant inflammatory response where interleukins are produced by affected tissues and the endothelial cells of the local capillary vasculature (11). Chemical signaling results in white blood cells being attracted to affected areas and attaching themselves to the endothelial lining of the capillaries, resulting in capillary blockage and further ischemia (11). It is recognized that cells can be programmed to die by cellular signaling mechanisms via the processes of apoptosis and autophagy.

**C. Mitochondrial Dysfunction**

Neurologic and myocardial dysfunction after successful resuscitation is prominent and mitochondrial dysfunction is a key determinant of poor outcomes (9, 12-16). Neurons and
cardiomyocytes, two high energy-consuming organs, are enriched with mitochondria and are highly sensitive to IR injury (17). The central nervous system receives almost a third of the CO (9). Morbidity and mortality after initially successful CPR can be attributed to immediate and delayed effects of reperfusion in the central nervous and cardiovascular systems (18). The principal role of mitochondria is to generate cellular energy (ATP) by the mitochondrial electron transport chain (ETC) through oxidative phosphorylation (OXPHOS). An adequate amount of energy by mitochondria is crucial for neuronal excitability and survival. In addition, mitochondria are critically involved in the regulation of cell death via apoptosis, autophagy and necroptosis (14, 19).

Mitochondrial dysfunction is one hallmark of IR injury, which induces neuronal death (9, 20). During the ischemic phase, OXPHOS is inhibited by lacking oxygen, causing low levels of adenosine triphosphate (ATP) and cellular acidification secondary to the diverging of glycolytic pyruvate to lactate (21). Upon reperfusion, the rapid re-establishment of OXPHOS induces several mitochondrial events such as ROS generation, H+ leaking, mitochondrial Ca\(^{2+}\) overload and the release of cell-death inducing protein cytochrome \(c\) (21).

Ultrastructural and functional injury occurs early in and progresses during ischemia (22). Mitochondrial morphological dynamics are relevant to IR injury (23, 24). Under physiological conditions, the removal of damaged or dysfunctional mitochondria is mediated by mitophagy, a mitochondrial-selective subtype of autophagy that involves sequestration and subsequent fusion of mitochondrial contents with lysosomes containing degradative enzymes (25, 26). This process allows maintenance of mitochondrial homeostasis; however, in the context of major cellular stress like that of IR or heart failure, mitochondrial DNA leak out from damaged and necrotic cardiomyocytes into the cytoplasm and extracellular space (26, 27). Mitochondrial DNA serves
as the damage-associated molecular patterns (DAMPs) that can activate several pro-inflammatory pathways, such as toll-like receptor (TLR) on immune cells such as circulating neutrophils and macrophages, leading to the formation of inflammatory cytokines TNFα and IL6 (Figure 1) (28-30). Mitochondrial DNA has also been shown to activate inflammasome complexes, which are responsible for recruiting active caspase-1 and converting pro-IL1β and proIL18 into their bioactive forms IL1β and IL18 (25, 31). Mitochondrial damage from cardiovascular events like IR thus appear to have major downstream effects on the development of inflammation, which may, in turn, influence the severity of the ischemic insult.
Figure 1. Role of TLR in production of inflammatory mediators. Adapted from (29).

An experiment with a mitochondrial protective agent (SS31) demonstrates improved cardiac contractility and ejection fraction (EF) with lower levels of inflammatory cytokines TNFα and IL1β (32). Translational studies have yielded similar results. Levels of circulating cell-free mitochondrial DNA were found to be a more accurate prognostic marker in CA patients (33). Additionally, in the COMICA study, higher serum levels of mitochondrial injury marker, cytochrome c, were seen in post-CA patients compared to controls. Even higher levels were seen in non-survivors versus survivors (34). Neurological outcomes in post-CA have not been as extensively studied. However, anti-inflammatory studies in a rat model of cerebral IR yielded comparable results with reduced cerebral infarct sizes, improved neurobehavioral scores and
lower levels of oxidative stress following treatment (35). Based on these findings, further research into agents that can attenuate the pro-inflammatory pathway in mitochondrial dysfunction could prove to be crucial in improving functional and mortality outcomes associated with IR.

Recognition of potential mitochondrial-driven pathology in IR has led to growing interest in investigating the relationship between mitochondrial injury and functional outcomes following SCA and IR. An imbalance in mitochondrial dynamics contributes to brain injury after cardiac arrest. Thus, targeting mitochondria is a promising neuroprotective strategy (36). Activation of the mitochondrial permeability transition represents a major mechanism of IR injury. A CB2 receptor agonist (JWH133) protected mitochondria against IR injury and reduced apoptosis through inhibition of apoptotic protein released from the mitochondrial permeability transition pore (MPTP) (37). Administration of the cannabinoid agonist WIN 55,212-2 after hypoxia ischemia in fetal lambs reduces brain injury, diminishing both apoptosis and mitochondrial dysfunction (38).

D. Post Cardiac Arrest Syndrome
Whole-body ischemia and reperfusion due to CA and subsequent ROSC constitute post-CA syndrome (PCAS) (39). PCAS is a combination of post-cardiac brain injury, circulatory dysfunction, systemic IR response and persistent precipitating pathology proposed by Nolan et al. in 2008 (40-42). Binks et al. state PCAS can be divided into four phases 1) immediate post-arrest (occurs in the first 20 minutes following ROSC) 2) early post-arrest (occurs between 20 minutes and 6 to 12 hours after ROSC) 3) intermediate (between 6 to 12 hours and 72 hours) 4) recovery (extends from 3 days and beyond) (43). Management of PCAS patients includes complex and multidisciplinary interventions. Early and intensive management should be focused on hemodynamic stability and neurologic recovery (42).
PCAS is most notably characterized by profound IR injury. Due to CA being an extreme of shock states, oxygen delivery is dramatically reduced during an arrest event, leading to profound tissue hypoxia (44). Depending on the cause of the arrest and severity of PCAS, many patients will require multiple organ support (45). Treatment received during this post-resuscitation period influences the overall outcome significantly, particularly quality of neurological recovery (45). Although CA impacts all organ systems, its impact is most profound on the neurological system as brain tissue is exquisitely sensitive to lack of oxygen (46). Post-CA anoxic brain injury is a major cause of morbidity and mortality, and is responsible for two thirds of intensive care unit (ICU) deaths in the post-CA period (47). Post–CA myocardial dysfunction also contributes to a low survival rate after in- and out-of-hospital CA. However, preclinical and clinical evidence indicates that this phenomenon is both responsive to therapy and potentially reversible (10).

Successful resuscitation from CA is usually characterized by the development of an IR syndrome of the body that may enhance cerebral and cardiac damage (41). The main determinant of this syndrome is a generalized activation of inflammatory reactions resulting in symptoms similar in many aspects to those of sepsis (48). Inflammatory responses play pivotal roles in the pathophysiology of cerebral and cardiac damage after CA/CPR (48-51). Systemic inflammation promotes disorders in the macro-circulation and micro-circulation and increases vascular permeability promoting protein extravasation and edema formation in the tissues, due to metabolic imbalance, leucocyte activation, endothelial toxicity and impairment of mitochondrial respiratory chain activity (40, 52).

Management of the post–CA patient is complex, and addresses multiple key issues simultaneously: diagnosing and treating the etiology, minimizing hypoxic brain injury, addressing sequelae of global IR injury, and managing cardiovascular dysfunction (53). Global
cerebral ischemia induced by CA and followed by reperfusion triggers a multitude of processes that ultimately result in neuroinflammatory responses with activation of glial cells, release of proinflammatory cytokines, and delayed neuronal death (54). Levels of TNFα and IL6 were shown to be strongly associated with the severity of PCAS, mortality rate, and neurologic outcomes (54). The severity of this syndrome will vary with the duration and cause of CA (45).

II. Role of Inflammatory Mediators in Cardiac Arrest
A. Pro-inflammatory mediators (Tumor Necrosis Factor α and interleukin 6)
Inflammatory responses play a pivotal role in the pathophysiology of brain and heart damage after CA/CPR, which leads to neuronal death, myocardial dysfunction, and apoptosis (55-57). Systemic and central nervous system (CNS) levels of various cytokines including tumor necrosis factor (TNF)α, interleukin (IL)1, IL6, IL8, IL10, and others are increased after CA (50, 51). One definitive mechanism of cerebral IR injury is inflammation. It is characterized by the activation of glial cells, influx of peripheral immune and inflammatory cells, high concentrations of ROS and release of pro-inflammatory mediators, including cytokines and adhesion molecules (58). The most studied cellular sources of ROS within the heart include cardiomyocytes, endothelial cells, and neutrophils (59). One function of cytokines is to change the physiological state of cells and the way they respond to environmental stimuli (60). TNFα induces inflammation, activates vascular endothelium, orchestrates the tissue recruitment of immune cells and promotes tissue destruction (60). Inflammation is a protective response of the host to infections and tissue damage, characterized by a series of reactions, including vasodilation and recruitment of immune cells and plasma proteins to the site of infection or tissue injury (61).

Normally, inflammation is beneficial to the host and can be resolved in a timely manner; however, deregulated inflammatory responses can cause excessive or long-lasting tissue damage, contributing to the development of acute or chronic inflammatory diseases (61). Increased
release of DAMP molecules and cellular dysfunction in activated microglia and astrocytes contribute to ischemia-induced cytotoxic and pro-inflammatory cytokine generation, and ultimately to delayed death of neurons (58). TNFα has been shown to play an important role in the pathogenesis of neurological diseases (62). It has been demonstrated that the brain and innate immune system are engaged in bidirectional cross-talk. The cerebral inflammatory cascade comprises an increase of neutrophil recruitment and peripheral macrophage infiltration, activation and migration of microglia, also known as brain macrophages and release of pro-inflammatory stimuli within the brain. When an ischemic event occurs, the normally immune-privileged brain environment collapses, DAMP molecules released by cellular injury can be recognized as invader to induce the activation of toll like receptors and triggers the activation process of nuclear factor κB (NFκB), which is linked to the transcription of numerous proinflammatory genes (58).

In the central nervous system, TNF is produced primarily by microglia and astrocytes in response to a wide range of pathological processes, including infection, inflammatory disease, ischemia and traumatic injury (63). This leads to neurologic damage. Cerebral injury is correlated to the abundant synthesis of inflammatory cytokines during CA and RES. In the brain, cytokines are not only produced by the cells of the immune system, but are also expressed in resident brain cells including neurons and glia. Neuroinflammation can continue for days and months, which contributes to neurological damage that ultimately determines the impaired recovery following CA/CPR (58). Increasing evidence reveals that suppressing the inflammatory process facilitates neuroprotection and has the potential for use in the clinical treatment of cerebral IR damage regarding CA (58).
Post-resuscitation myocardial dysfunction has been ascribed to post-ischemic stunning, the pathobiology of which has been well described in models of global and regional myocardial ischemia and reperfusion (64). Tumor necrosis factor (TNF) has been implicated in the pathogenesis of a number of cardiovascular diseases, including atherosclerosis, myocardial infarction, heart failure, myocarditis and cardiac allograft rejection, and vascular endothelial cell responses to TNF may underlie vascular pathology in many of these conditions (63). TNFα increases during the early post-resuscitation period and may play a role in post-resuscitation myocardial dysfunction (64). Niemann et al. show the time courses of LV systolic and diastolic dP/dt and TNFα are significantly negatively correlated. TNFα concentration is a statistically significant predictor of systolic dP/dt, with higher TNF concentrations being associated with decreased left ventricular systolic function (64). Hemodynamic effects of TNFα are characterized by decreased contractility, reduced EF, decreased systemic vascular resistance, hypotension, and biventricular dilation. TNFα is believed to exert its myocardial depressant effect by disrupting calcium homeostasis or calcium sensitivity and the normal myocardial contraction relaxation cycle (64).

Cardiotoxicity is primarily attributed to TNF-induced cardiomyocyte apoptosis (60). The inflammatory response after ROSC is characterized by polymorphonuclear leukocyte activation, adhesion molecule expression, reactive oxygen species (ROS) production from inducible nitric oxide synthase (iNOS), and release of cytokines such as TNFα and interleukin 6 (IL6) (7). IL6 represents a keystone cytokine in infection, cancer and inflammation, in which it drives disease progression or supports the maintenance of immunological reactions (65). An enormous repertoire of biological functions can be attributed to the cytokine IL6, establishing IL6 as a pleiotropic cytokine and a major player in health and disease (66). Soluble ambient IL6 is
available during massive inflammation (66). Baseline IL6 was a good predictor of in-hospital mortality and poor functional outcome. It was associated with mortality in multivariable analysis (51). IL6 has context-dependent pro- and anti-inflammatory properties and is regarded as a prominent target for clinical intervention (65).

Cytokine production is also altered by stress. Increased production of TNFα, IL6 and IL1β contributes to the acute-phase reaction and hypermetabolic response that accompanies overwhelming infection, hemorrhage, injury and surgery (64). These stress-activated cytokines all have the potential to produce cardiac decompensation when in sufficiently high concentrations (64). The effects of stress-activated cytokines extend beyond the myocardium.

B. S100A8 and S100A9
S100A8 and S100A9, also known as myeloid-related protein 8 (MRP8) and MRP14 respectively, are DAMPs that belong to the S100 family. Both are constitutively expressed in neutrophils, monocytes and dendritic cells. However, they can also be intensely upregulated upon the onset of trauma, infection, stress and other inflammatory processes (67-70). Under physiological conditions they can exist as homodimers, but under inflammatory states they preferentially form heterodimers with each other (S100A8/A9) because the heterodimeric structure confers increased resistance to the protease-rich environment of inflammation (71). Additionally, S100A8 and S100A9 contain a characteristic helix-loop-helix motif with charged amino acid residues, giving them a high affinity for divalent ions such as calcium (69).

Therefore, they are calcium-binding proteins that have been implicated as key modulators in the development of inflammation (67). Together, these features allow S100A8 and S100A9 to achieve functional diversity both intracellularly and extracellularly (69). They are able to exhibit both intracellular and extracellular effects on various cells of the innate immune system and have therefore become a point of interest for therapeutic intervention (Figure 2) (67, 70).
Figure 2. Involvement of S100 proteins in stress and inflammation. Adapted from (70)

Intracellular S100A8/A9 is best known for the ability to regulate trans endothelial migration of leukocytes (72). Transmigration is primarily achieved through extensive remodeling of the cytoskeletal structures which, in turn, is controlled by elevation of intracellular calcium levels and specific protein phosphorylation (72). As S100A8 and S100A9 are the major calcium-binding proteins expressed in neutrophils and monocytes, it has been demonstrated that calcium-
induced S100A8/A9 complexes promote microtubule polymerization via direct interaction with tubulin (72).

Extracellular S100A8 and S100A9 function primarily as DAMP molecules after being released from damaged or activated cells. The exact secretion mechanism remains unknown; however, it appears to require monocytic activation of both protein kinase C and the receptor for advanced glycation end products (RAGE) pathways (73, 74). Once released, S100A8/A9 exerts its effects through two different innate immune receptors: TLR4 and RAGE (67). Upon binding to TLR4 on phagocytes, S100A8/A9 triggers the MyD88-dependent pathway, where MyD88 recruits and activates IL1R-associated kinases (IRAKs) and TNFR-associated factor 6 (TRAF6). This, in turn, causes a downstream signaling cascade, ultimately leading to loss of inhibition of transcription factors NF-κB and AP-1. These factors can then translocate the nucleus and induce expression of pro-inflammatory cytokines such as TNFα, IL6 and IL8 (Figure 3) (69). Similarly, binding to RAGE results in subsequent activation of JNK and JAK-STAT signaling (75). Effects are under investigation but appear to inhibit anaerobic glycolysis in myocardium in the setting of ischemia (76). Overall, S100A8/A9 serves as a key modulator in the early stages of inflammation and can have a profound impact on long-term severity of inflammatory diseases.
C. Anti-inflammatory mediators (interleukin 10)
Anti-inflammatory cytokines, such as IL10, have been shown to inhibit the LPS-induced production of pro-inflammatory cytokines (78). IL10 is a secondary cytokine released by leukocytes or endothelial cells following stimulation by IL1β and TNFα (51). IL6 might also contribute to the regulation of inflammation by inducing IL10-producing B regulatory (Breg) cells (66). Zhang et al show an elevated level of IL-10 attenuates LPS-induced activation of NF-κB, JNK, ERK and p38MAPK, which results in reduced production of TNFα and IL6 (78).
Understanding the role of IL10 in the regulation of metabolic processes is essential both for deciphering how IL10 acts to control inflammatory responses and for discovering key molecular controlling processes involved in the resolution of inflammation (79). IL10 production was first
described in T\(_{H2}\) cells where its expression accompanies that of the T\(_{H2}\) type cytokines IL4, IL5 and IL13 (80).

In the absence of IL-10 signaling, macrophages accumulate damaged mitochondria in a mouse model of colitis and inflammatory bowel disease, which results in dysregulated activation of the NLRP3 inflammasome and production of IL-1β (79). The absence of IL10 leads to ROS production from accumulated mitochondria (79). Various cell types can express IL-10, which makes IL10 regulation challenging (80). IL10 might act to reverse the metabolic program associated with inflammatory response (79).

III. Cannabinoids
   A. Endocannabinoid System (ECS)

The psychoactive properties of marijuana have been known for thousands of years, however, the biological basis of the effects of marijuana and its bioactive ingredients, collectively called cannabinoids, has unfolded in the last few decades (81, 82). Since 1998, the use of cannabis for medical purposes has become legal in 29 states (according to state, but not federal law) in the USA, and numerous countries have also opted to legalize marijuana for medicinal use (83). Cannabinoid compounds are being extensively studied for therapeutic potential. Although there is an abundance of information on the role of cannabinoids in the central and peripheral nervous systems, their role in the cardiovascular system is more complex (84). Cannabinoids and their synthetic and endogenous analogs are best known for prominent psychoactive properties, however, their cardiovascular effects were recognized as early as the 1960’s (85). Cannabinoids are highly lipophilic molecules that have been shown to alter the functional activities of immune cells \textit{in vitro} and \textit{in vivo}. The term “exogenous cannabinoid” has been applied to cannabinoids that are extracted from the marijuana plant \textit{cannabis sativa} or are
synthesized in the laboratory (86). WIN55,212-2 (WIN55) is an exogenous cannabinoid (Figure 4).

**Figure 4. WIN55 is a full agonist for CB₁ and CB₂ (87)**

Cannabinoids modulate inflammation through multiple pathways (88). They have been reported to have immunosuppressive activity and alter macrophage functions (89). It has been reported that, under pathological conditions, cannabinoids can avoid mitochondrial dysfunction, thus inhibiting apoptotic signaling (38). Cannabinoids were shown in vivo and in vitro, to exert their immunosuppressive properties through 4 main pathways: induction of apoptosis, inhibition of cell proliferation, inhibition of cytokines, and chemokine production and induction of regulatory T cells (tregs) (90). Distinct phytocannabinoids may activate immune cells by receptor-mediated as well as by non-receptor mediated modes (91). Cannabidiol inhibits IL1, IL12, TNF-α and interferon-gamma cytokine release by peripheral blood mononuclear cells, and
enhances production of the Th2-associated cytokines, IL4 and IL10 (90). The ECS, which comprises specific cannabinoid receptors, endogenous ligands (endocannabinoids), and synthetic and degradative pathways, is a new therapeutic target in a variety of disorders, such as inflammation and tissue injury, including the cardiovascular system (37).

**B. Cannabinoid Receptors**

Endocannabinoids (eCBs) act locally in a paracrine or autocrine manner by activating cannabinoid receptors (83). The endocannabinoid signaling system has emerged as an important target for therapeutic drug development, although the design of receptor-selective ligands has remained a challenge (92). Endocannabinoids may limit hepatic injury by modulating the expression of adhesion molecules and the infiltration and activation of inflammatory cells by CB2 dependent mechanisms, which is consistent with the emerging role of CB2 receptors in regulating microglial cell function and neuroinflammation (8). The discovery of cannabinoid receptors that mediate the action of THC and synthetic cannabinoids, precipitated the search for the endogenous ligands that bind these receptors. Arachidonoyl ethanolamide or anamide (AEA) and 2-arachidonoylglycerol (2-AG) represent the primary endogenous ligands that bind and activate CB1 and CB2 (91).

These cannabinoid receptors belong to the G-protein coupled receptor family and play a key role in downstream intracellular regulation of apoptosis and inflammation (82). Both receptors have seven transmembrane domains, are coupled to inhibitory G proteins, and are linked to signaling cascades that may involve adenylyl cyclase and cAMP, mitogen-activated protein (MAP) kinase, and the regulation of intracellular calcium (91). Cannabinoid receptors signal via G_{i/o}-protein-dependent pathways to inhibit adenylyl cyclase and modulate ion-channel function, but also activate mitogen-activated protein kinases (p44/42 MAPKs, p38, ERK, and JNK) or ceramide signaling, and can also engage G-protein-independent pathways via β-arrestins.
(Figure 5) (83). Saroz et al. recently reported CB₂ activation induces simultaneous Gαᵢ and Gαₛ (G protein-stimulating adenylate cyclase) coupling, which produces a delayed cAMP flux in human primary leukocytes (93, 94). The cannabinoid system with its receptors (CB₁ and CB₂), provides neuroprotection against cerebral and spinal cord ischemia-reperfusion (IR) injuries (95). During ischemic injury, endocannabinoids accumulate, cannabinoid receptors are up-regulated, and treatment with cannabinoid agonists (either endocannabinoids or phytocannabinoids/synthetic cannabinoids) protects neurons against damage resulting from ischemic stroke (96).
Figure 5. Cannabinoid receptor signaling (a) The adenylate cyclase (AC) pathway. $G_{\alpha i}$ signaling downregulates the pro-inflammatory immune response via adenylate cyclase. CB$_2$ couples predominantly to $G_{\alpha i/o}$, resulting in adenylcyclase inhibition (b) The mitogen-activated protein kinase (MAPK) pathway. CB$_2$ $\beta_{5}$ subunit mediated activation of the MAPKs extracellular regulated kinase (ERK1/2), p38 and janus-kinase (JNK)(86, 97). The CB$_2$ receptor is coupled with $G_{\alpha i/o}$ and $G_{\alpha q}$ (G protein-activating phospholipase C and G protein-increasing cytosolic Ca$^{2+}$) (94).

In the cardiovascular system, cannabinoid receptors are located in the myocardium, vascular endothelial and smooth muscle cells, as well as circulating blood cells (83). Both CB$_1$
and CB₂ receptor signaling modulate remote ischemic preconditioning-induced cardio protection (98). Endocannabinoids overproduced during various forms of IR injury have been proposed to protect against myocardial IR injury and to contribute to the ischemic preconditioning effect of endotoxin, heat stress, or brief periods of ischemia, while these lipid mediators may also mediate the cardiovascular dysfunction in these pathologies (99).

In a whole animal model of myocardial IR injury induced by coronary occlusion/reocclusion in anesthetized mice, the protective role of CB₂ but not CB₁ receptor activation was determined (8). Cannabinoid receptor 2 could potentially mediate protection against the four phases after resuscitation (thought to occur depending on the degree and duration of organ ischemia): 1. first 24 hours after the event—a microcirculatory dysfunction from the multifocal hypoxia leads to rapid release of toxic enzymes and free radicals into the cerebrospinal fluid and blood; 2. 1 to 3 days—cardiac function and systemic function improve, but intestinal permeability increases predisposing the patient to sepsis syndrome leading to multiple organ dysfunction syndrome; 3. Days after cardiac arrest—a serious infection may occur, and the patient declines rapidly, and; 4. The patient eventually dies (48). “Myocardial stunning” classically defined as temporary mechanical dysfunction persisting after episodes of ischemia and reperfusion with the absence of irreversible histological damage is also responsive to therapeutic initiatives, namely inotropic therapy or even antioxidants or calcium antagonists for implementing prevention strategies (100).

In addition to the cell-surface cannabinoid receptors, there is growing evidence that the intracellular peroxisome proliferator-activated receptors (PPARs) are cannabinoid targets (101). There are other non-CB₁/CB₂ receptors—such as GPR55, GPR119 and TRPV1 that are phylogenetically unrelated to the CB₁ or CB₂ receptors but have the ability to respond to
endocannabinoids (102). PPARγ is a nuclear hormone receptor that regulates gene expression as a ligand-activated transcription factor and, in the central nervous system, is expressed on oligodendrocytes and astrocytes as well as neurons in multiple brain areas (103). WIN55 has been reported to reduce inflammation in murine brain ECs through PPARγ, independent of CB1 and CB2. This mechanism needs further exploration (104) as nuclear transcription factors play an important role in the regulation of initiation and resolution of the inflammatory process (Figure 6) (105). Direct binding of PPARs and the indirect effect of these receptors stimulate production of antioxidant enzymes and inhibit NFκβ (105). Activated PPARγ with endogenous or synthetic ligands can not only directly combine with the p50/p65 dimer and form a new complex that downregulates the NFκβ signaling pathway but also upregulate the expression of IκBα and indirectly inhibit the transcriptional activity of NFκβ (106).
Figure 6. Cross-talk between PPARs and TLRs and NFκβ. Adapted from (105)

C. Anti-inflammatory properties of CB2
The first record of medical application of the strong anti-inflammatory effect of cannabinoids comes from the world’s oldest pharmacopoeia, which was found in China (82).

Endocannabinoids mediate inflammation by regulating cytokines at different steps throughout the inflammatory response (88). CB2 receptors are expressed mostly in the immune system, including the thymus, spleen, lymphatic nodes, and circulating leukocytes, where they mediate cytokine release (82). Levels of CB2 expression varies among different immune cell populations, with B lymphocytes expressing the highest levels followed by macrophages, monocytes, natural killer (NK) cells, and polymorphonuclear cells, in that order (91). An important development has
been the identification of low levels of CB$_2$ receptor expression in tissues previously thought to be devoid of these receptors. These include specific regions of the brain (*Figure 7*), spinal cord and dorsal root ganglia, neurons in the myenteric and submucosal plexus of the enteric nervous system, in myocardium or cardiomyocytes (*Figure 8*), human vascular smooth muscle and endothelium, activated hepatic stellate cells, Kupffer cells, in reproductive organs/cells, colonic epithelial cells, bone, mouse and human exocrine and endocrine pancreas, and in various human tumors (107). An interesting biologic property of CB$_2$ receptors is their high inducibility, with CB$_2$ mRNA levels often increasing as much as 100-fold following nerve injury or during inflammation (108).

*Figure 7*. Brain CB$_2$ expression and function and association with neuropsychiatric and neurological diseases. Adapted from (109).
Figure 8. Mapping of cannabinoid-sensitive receptors and eCBs in the heart (97).

A large body of preclinical research demonstrates the effectiveness of cannabinoids in rodent models of acute and chronic inflammatory pain, as well as neuropathic pain (88). The inflammatory response to insult must be tightly regulated in order to minimize damage to healthy tissues. Thus, in addition to proinflammatory cytokines, active immune cells produce and release anti-inflammatory mediators, including IL10, which are regulated by the endocannabinoid system (88). Accumulating evidence supports the development of selective CB2 receptor agonists for the management of acute tissue injury associated with inflammation (such as myocardial infarction, stroke, or organ transplantation) (83). Since CB2 activation dampens inflammatory responses in the absence of psychotropic effects, it has the potential to serve as a molecular target for attenuating inflammation linked to pathogenic disorders (91). Consistent with the protective role of CB2 receptor activation, CB2−/− mice develop increased IR
induced tissue damage and proinflammatory phenotype (8). Selective activation of the CB₂ receptor a few minutes before reperfusion markedly improves myocardial infarction (110).

Mechanistic investigations reveal that the protective effect of CB₂ receptor may ascribe to reduction of cardiac leukocyte recruitment, reduction of superoxide generation, or increase of ERK1/2 and STAT-3 phosphorylation (37). CB₂ signaling in the heart and vasculature may activate cardioprotective mechanisms and limit inflammation (Figure 9) (107). Evidence from in vitro and in vivo models suggests that CB₂ activation might reduce atherosclerotic inflammation (110). CB₂ receptor stimulation limits hepatic injury by decreasing the expression of ICAM-1, CVAM-1, neutrophil infiltration, TNFα, chemokine (MIP-1α and MIP-2) levels, and lipid peroxidation. The decrease in lipid peroxidation can be secondary to the decrease of inflammatory cell infiltration and activation (8). However, the lack of highly selective CB₂ receptor antibodies limits interpretation of some studies. Thus, the use of stringent negative controls is crucial for the correct detection and quantification of protein targets (88).

Figure 9. Cardiac impact of cannabinoid receptors. Adapted from (97).
Collectively, a number of studies suggest that exogenous cannabinoids elicit a shift in the cytokine expression profile from that which is Th1 proinflammatory to one that is Th2 anti-inflammatory and that the CB2 receptor may be linked to this effect (111). It has been observed that the CB2 agonist HU-308 attenuated hepatic ischemia/reperfusion injury by decreasing levels of TNFα, MIP-1α and MIP-2 in serum and liver homogenates (112). Cannabinoid CB2 receptor knockout (CB2−/−) mice are fertile, care for their offspring, and have a similar phenotype as their wild-type littermates (8), which shows CB2 knockout is not lethal.

Possible mechanisms between systemic inflammation and hemodynamics have not been fully characterized but direct effects of inflammatory mediators on the contractility of the myocardium and vascular smooth muscle have been suggested (113). Though WIN55 has been demonstrated to have anti-inflammatory and anti-oxidative effects in inflammatory or ischemia diseases independent of its hypothermic effects, previous studies could not exclude other effects (114). Recent studies have indicated that activation of CB2 leads to an anti-inflammatory response; therefore, the beneficial effects of WIN55 following resuscitation may be related to both CB1 and CB2 receptor activation.

IV. Research Objectives
Cannabinoids produce hypothermia in normal rats through the activation of central CB1 receptors. WIN55, the nonselective cannabinoid CB1/CB2 receptor agonist, produced hypothermia in a dose-dependent manner when injected intramuscularly. The body temperature reduced from 37 to 34°C, 60 to 180 mins post injection and hypothermia was maintained up to 5 hours. The effect was completely blocked by the selective CB1 antagonist SR141716A (115, 116). CB2 receptor ligands have potential therapeutic applications as immunomodulators for the treatment of inflammation (117). Hypothesized effects of WIN55 summarized in Figure 10.
Figure 10. WIN55, 212-2 can be coupled to either CB$_1$ or CB$_2$ with different functional consequences.

The effects of WIN55 were investigated initially in our rat model of CA and CPR. WIN55 was selected based on the following reasons: 1) the described hypothermia effect of CB$_1$ agonist is convincing and well documented, 2) it is highly selective for cannabinoid receptors and interacts negligibly with other neurotransmitter and ion channels (118), 3) it is expressed in thermoregulatory areas of the central nervous system and therefore decreases body temperature via a central mechanism (119), 4) It has been shown to be neuroprotective (120) and 5) It has been demonstrated in both mice and rats that the CB$_2$ receptor activation effects of WIN55 have significant anti-inflammatory effects (121-123). CB$_2$ expression has been demonstrated in cardiac myocytes and endothelial and smooth muscle cells of coronary arteries (84).

**Hypothesis:** Cardiac arrest will cause mitochondrial dysfunction and increase plasma concentrations of TNFα, IL6 and IL10. IM Administration of SR141716A before VF+CPR followed by infusion of WIN55 5 min after ROSC will prohibit the release of inflammatory mediators caused by cardiac arrest via the CB$_2$ receptor.
CHAPTER 2: Materials and Methods

I. Reagents

Lipopolysaccharide (LPS), sodium chloride (NaCl), (R)-(+-)WIN55,212-2 mesylate salt, polysorbate 80, dimethyl sulfoxide, DTT (Pro#1000748546), iodoacetamide (Pro#122270250), LC-MS/MS grade water, methanol, acetonitrile and common laboratory chemicals were purchased from Sigma Aldrich (St. Louis, MO). Pierce Trypsin Protease, MS grade (Pro#90057), Pierce BCA Protein Assay Kit (Pro#23250) and Formic Acid Optima LC/MS (A11-50) were purchased from Fisher Scientific (Waltham, MA). A TMT10plex Isobaric Label Reagent Set plus TMT11-131C Label Reagent (A34808) was purchased from Thermo Scientific (Rockford, IL). Dulbecco’s Modified Eagle Medium (DMEM), 100x Penicilin/Streptomycin and 1M HEPES were obtained from Life Technologies, Gibco (Waltham, MA). Heat inactivated Fetal Bovine Serum (FBS) was from Atlanta Biologicals (Flowery Branch, GA). CB1 receptor antagonist SR141716A and (+)-WIN55,212-2 (mesylate) were purchased from Cayman Chemicals (Ann Arbor, MI).

II. In vivo-Mitochondria

Guanghui Zheng performed surgical technique, Xianfei Ji performed mitochondrial isolation and measurement and helped draft manuscript, Jeremy Thompson trained Xianfei Ji and Jennifer Bradley on all mitochondrial techniques, Rabiya Shabnam ran ETC assay, Jennifer Bradley analyzed all data and drafted manuscript and Qun Chen, Edward Lesnfsky and Wanchun Tang reviewed data and manuscript drafts. This study was approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University. Animal care and handling were in
accordance with the Guide for the Care and Use of Laboratory Animals and the ARRIVE guidelines.

**Animal Preparation**

Male Sprague Dawley rats, weighing between 450g and 550g were anesthetized by intraperitoneal injection of pentobarbital (45 mg/kg). The trachea was orally intubated with a 14-gauge cannula (Abbocath- T; Abbott Hospital Products Division, North Chicago, IL). End-tidal CO\(_2\) (ETCO\(_2\)) was continuously monitored with a side-stream infrared CO\(_2\) analyzer (Capstar-100 Carbon Dioxide Analyzer; CWE, Ardmore, PA). A conventional lead II electrocardiogram (ECG) was monitored continuously. A PE-50 catheter (Becton Dickinson, Franklin Lakes, NJ, USA) inserted into the descending aorta measured arterial pressure. A thermocouple microprobe (9030-12-D-30, Columbus instruments, Columbus, OH, USA) inserted into the left femoral vein measured blood temperature. Another PE-50 catheter advanced into the right atrium measured right atrial pressure. A 3F catheter (Model C-PMS-301J; Cook Critical Care, Bloomington, IN) advanced into the right atrium was utilized to advance a pre-curved guidewire into the right ventricle to induce VF. Aortic blood temperature was maintained at 37°C ± 0.5°C by a heated surgical board. ECG, aortic and right atrial pressures, ETCO\(_2\), and blood temperature were continuously recorded on a personal computer–based data acquisition system supported by WINDAQ software (DATAQ, Akron, OH).

**Experimental Procedures**

Animals were randomized into 4 groups (n=6 each group): 1) Sham (underwent surgery, no VF or CPR), 2) VF (VF only for 8 min), 3) VF+CPR (VF 8 min + CPR 8 min, no defibrillation) and 4) Return of Spontaneous Circulation (ROSC 1 hr) (VF 8 min, CPR8 min, defibrillation, and observe 1 hr after ROSC) (*Figure 11*). Mechanical ventilation was established at a tidal volume
of 0.60 mL/100g of body weight, a frequency of 100 breaths/min, and FiO2 of 1.0. VF was then induced with a progressive increase in 60-Hz current to a maximum of 3.5 mA delivered to the right ventricular endocardium. Current flow continued for 3 min to prevent spontaneous defibrillation. After 8 min of untreated VF, precordial chest compressions, together with mechanical ventilation, were initiated using a pneumatically driven mechanical chest compressor. Precordial chest compressions were maintained at a rate of 200/min and synchronized to provide a compression/ventilation ratio of 2:1 with equal compression-relaxation for 8 min. Defibrillation was attempted with up to three 4-J counter shocks. ROSC was defined as the return of supraventricular rhythm with a mean aortic pressure (MAP) above 50 mm Hg for 5 min.

**Figure 11. In vivo-Mitochondria Experimental Protocol** - N=6 for each group. Sham is time zero control.

Cardiac mitochondria were isolated by a method previously described with slight modifications (124, 125). Hearts were removed and placed into buffer A [100 mM KCl, 50 mM 3-(N-morpholino) propanesulfonic acid (MOPS), 1 mM EGTA, 5 mM MgSO4-7 H2O, and 1
mM ATP, pH 7.4] at 4°C. Cardiac tissue was finely minced and placed in buffer A containing 0.2% bovine serum albumin (BSA) and homogenized with a polytron tissue processor (Brinkman Instruments, Westbury, NY) for 2.5 s at a rheostat setting of 14. The polytron homogenate was centrifuged at 2,200 rpm for 10 min, supernatant was saved for isolation of subsarcolemmal mitochondria (SSM), and the pellet was washed. Combined supernatants were centrifuged at 5,000 rpm for 10 min to sediment SSM. Interfibrillar mitochondria (IFM) were isolated by incubation of skinned myofibers, obtained after polytron treatment (2.5 sec at a setting of 14), with 5 mg/g (wet weight) trypsin for 10 min at 4°C. SSM and IFM were washed twice and then suspended in 100 mM KCl, 50 mM MOPS, and 0.5 mM EGTA. Mitochondrial protein concentration was measured by the Lowry method using BSA as a standard (125).

Brain mitochondria were isolated by a method previously described with slight modifications (126). Brain (cerebrum) was rapidly removed and homogenized at 4°C in 10ml of isolation buffer B (215mM mannitol, 75mM sucrose, 20 mM HEPES, 1mM EGTA, pH 7.4) containing 5mg of the bacterial protease type VIII (Subtilsin A). Brain homogenates were brought to 30 ml and then centrifuged at 12,000 rpm for 10 min. The pellet was resuspended in 10 ml of buffer C (buffer B+1mg/ml bovine serum albumin) and centrifuged at 2,420 rpm for 10 min. The mitochondrial pellet was resuspended in 10 ml of buffer C and centrifuged at 2,420 rpm for 10 min. Combined supernatants were centrifuged at 9,000 rpm for 10 min. The pellet was then resuspended in 3 ml buffer C, and centrifuged at 9,000 rpm for 10 min. The pellet was resuspended in 2 ml buffer B, and centrifuged at 9,000 rpm for 10 min. Finally, the mitochondrial pellet was resuspended in 100 μl buffer B.

Measurements
Oxygen consumption in mitochondria was measured using a Clark-type oxygen electrode at 30°C as previously described (127, 128) using glutamate (20 mM) (complex I substrate), succinate (20 mM) (complex II substrate), plus 7.5 mM rotenone and N,N,N’,N’ tetramethyl p-phenylenediamine (TMPD; 1 mM)-ascorbate (10 mM) (complex IV substrate) + rotenone (Figure 12). Maximal ADP-stimulated respiration (2 mM ADP) was determined. Mitochondria were used within 6 hrs after isolation.

Enzyme activities were measured spectrophotometrically in detergent-solubilized frozen-thawed mitochondria using previously described methods (129): NADH-ubiquinone oxidoreductase, rotenone-sensitive (complex I=340nm), NADH-ferricyanide reductase (NFR=340nm); succinate-ubiquinone oxidoreductase, thenoyltrifluoroacetone sensitive (complex II=600nm); ubiquinol-cytochrome c oxidoreductase, antimycin A sensitive (complex III=550 and 600nm); and citrate synthase (≈412nm). Frozen-thawed mitochondria were solubilized at a
final protein concentration of 1 μg/μl in 0.5% cholate in MSM/EDTA buffer, pH 7.4 (220 mM mannitol, 70 mM sucrose, 5 mM MOPS, 2 mM EDTA) (130).

Calcium retention capacity (CRC) was used to assess calcium-induced MPTP opening as previously described (131) in mitochondria (125 μg/ml) incubated in medium containing 150 mM sucrose, 50 mM KCl, 2 mM KH$_2$PO$_4$, 5 mM succinate, in 20 mM Tris·HCl, pH 7.4, by sequential pulses of 5 nmol calcium. Extramitochondrial Ca$^{2+}$ concentration was recorded with 0.5 μM calcium Green-5N (Life Technologies City State), and fluorescence monitored with excitation and emission wavelengths at 500 and 530 nm, respectively (131). The calcium retention capacity CRC assay measures the susceptibility to opening of the permeability transition pore; and is performed in a non-acidic environment.

III.  \textit{In vivo-Proteomics}

Fenglian He and Christine Moore performed surgical technique, Gea-Ny Tseng performed tissue lysate preparation and Poochon Scientific LLC performed proteomic analysis. Jennifer Bradley reviewed proteomic results focusing on S100A8/A9 expression (132) and found it increased within LV Apex Epicardium following CA and CPR. This study was approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University. Animal care and handling were in accordance with the Guide for the Care and Use of Laboratory Animals and the ARRIVE guidelines.

\textbf{Animal Preparation}

Male Sprague Dawley rats, weighing between 450g and 550g were anesthetized by intraperitoneal injection of pentobarbital (45 mg/kg). The trachea was orally intubated with a 14-gauge cannula (Abbocath- T; Abbott Hospital Products Division, North Chicago, IL). ETCO$_2$ was continuously monitored with a side-stream infrared CO$_2$ analyzer (Capstar-100 Carbon
Dioxide Analyzer; CWE, Ardmore, PA). A conventional lead II ECG was monitored continuously. A PE-50 catheter (Becton Dickinson, Franklin Lakes, NJ, USA) inserted into the descending aorta measured arterial pressure. A thermocouple microprobe (9030-12-D-30, Columbus instruments, Columbus, OH, USA) inserted into the left femoral vein measured blood temperature. Another PE-50 catheter advanced into the right atrium measured right atrial pressure. A 3F catheter (Model C-PMS-301J; Cook Critical Care, Bloomington, IN) advanced into the right atrium was utilized to advance a pre-curved guidewire into the right ventricle to induce VF. Aortic blood temperature was maintained at 37°C ± 0.5°C by a heated surgical board. ECG, aortic and right atrial pressures, ETCO₂, and blood temperature were continuously recorded on a personal computer–based data acquisition system supported by WINDAQ software (DATAQ, Akron, OH).

Experimental Procedures

Animals were randomized into 3 groups: 1) Sham (underwent surgery, no VF or CPR) (n=4), 2) CPR (VF 8 min + CPR 8 min, defibrillation and ROSC) (n=4), 3) Norm (nothing done to animal) (n=3) (Figure 13). Mechanical ventilation was established at a tidal volume of 0.60 mL/100g of body weight, a frequency of 100 breaths/min, and FiO₂ of 1.0. VF was then induced with a progressive increase in 60-Hz current to a maximum of 3.5 mA delivered to the right ventricular endocardium. Current flow continued for 3 min to prevent spontaneous defibrillation. After 8 min of untreated VF, precordial chest compressions, together with mechanical ventilation, were initiated using a pneumatically driven mechanical chest compressor. Precordial chest compressions were maintained at a rate of 200/min and synchronized to provide a compression/ventilation ratio of 2:1 with equal compression-relaxation for 8 min. Defibrillation
was attempted with up to three 4-J counter shocks. ROSC was defined as the return of supraventricular rhythm with a MAP above 50 mm Hg for 5 min.

**Figure 13. In vivo-Proteomics Experimental Protocol**

**Measurements**

Once ROSC was reached Christine Moore or Dr. Tseng removed the heart for further analysis. Samples sent to Poochon Scientific were labeled Left Ventricle Apex epicardial (LV Apex EPI) (**Figure 14**).
**Figure 14. LV Apex Epi**- Samples sent to Poochon Scientific for further analysis were labeled LV Apex Epi from Dr. Tseng’s laboratory. Adapted from (133).

**General Protocol of protein lysate preparation performed by Dr. Tseng’s laboratory**

RIPA buffer: 20mM Tris-HCL pH7.4, 150mM NaCl, 1mM EDTA, 1% Triton-X100, 1% sodium deoxycholate, 0.1% SDS with freshly added PMSF to 1mM and with freshly added aprotinin and leupeptin to 5ug/ml was prepared just before use. The left ventricular (LV) apex was removed and placed in RIPA on ice for 10 min before homogenizing. Tissue was kept on ice during homogenization until tissue was liquified. Then liquified tissue lysate was centrifuged at 13,000 rpm for 3min at 4°C. Clear supernatant was transferred to new clearly labelled tubes for shipment to Poochon Scientific (134).

**BCA Assay performed by Poochon Scientific**
Tissue lysate samples were thawed at room temperature and a precipitation (cloud) was observed. 20 µl of 10% SDS was added to the sample and heated at 95°C for 10 minutes. After treatment the lysate became clear. Protein concentration of supernatant was determined by a BCA™ Reducing Reagent compatible assay kit from Thermo Scientific (Rockford, IL). The BCA Protein Assay is a popular method for colorimetric detection and quantitation of total protein (135). The assay was read at an optical density (OD) of 562nm. One major advantage of the BCA assay is that it produces a linear response curve. This response curve allows accurate determination of unknown protein concentrations and provides a higher dynamic range than other standard assays (135).

**TMT-11plex labeling performed by Poochon Scientific**

100 µg of protein lysate was taken from each sample for in-solution trypsin digestion. Predigestion was ran along with digested samples on SDS-PAGE and stained to check digestion efficiency. Isobaric labeling was performed using a commercial TMT10plex Isobaric Label Reagent Set plus TMT11-131C Label Reagent kit according to the product manual and samples were labeled as described in Table 1. The 11 labeled peptide mixture was then dried in a vacuum concentrator and stored at -80 ºC for the next step.
Table 1. Summary of 11 cell pellet sample labeling

<table>
<thead>
<tr>
<th>Sample Label</th>
<th>Description</th>
<th>TMT-tag</th>
<th>TMT Quantification (ratio)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>Norm_1</td>
<td>126</td>
<td>126/131</td>
</tr>
<tr>
<td>S2</td>
<td>Norm_2</td>
<td>127C</td>
<td>127C/131</td>
</tr>
<tr>
<td>S3</td>
<td>Norm_3</td>
<td>127N</td>
<td>127N/131</td>
</tr>
<tr>
<td>S4</td>
<td>CPR_1</td>
<td>128C</td>
<td>128C/131</td>
</tr>
<tr>
<td>S5</td>
<td>CPR_2</td>
<td>128N</td>
<td>128N/131</td>
</tr>
<tr>
<td>S6</td>
<td>CPR_3</td>
<td>129C</td>
<td>129C/131</td>
</tr>
<tr>
<td>S7</td>
<td>CPR_4</td>
<td>129N</td>
<td>129N/131</td>
</tr>
<tr>
<td>S8</td>
<td>Sham_1</td>
<td>130C</td>
<td>130C/131</td>
</tr>
<tr>
<td>S9</td>
<td>Sham_2</td>
<td>130N</td>
<td>130N/131</td>
</tr>
<tr>
<td>S10</td>
<td>Sham_3</td>
<td>131</td>
<td>131/131</td>
</tr>
<tr>
<td>S11</td>
<td>Sham_4</td>
<td>131C</td>
<td>131/131-C</td>
</tr>
</tbody>
</table>

Fractionation of labeled peptides by basic reversed phase UHPLC

Dried labeled peptides were resuspended in 10 mM TEABC. Labeling efficiency was determined before fractionation by analysis of a small sample aliquot (1%). A minimum labeling efficiency of 95% was required. The fractionation of TMT-10plex labeled peptide mixture was carried out using an Agilent AdvanceBio Column (2.7 µm, 2.1 x 250 mm) at Solvent A (10 mM TEABC, pH 8.0) and an Agilent UHPLC 1290 system. Separation was performed by running a gradient of Solvent B (10 mM TEABC, pH 8.0, 90% ACN) and Solvent A (10 mM TEABC, pH 8.0) at a flow rate 250 µL/min. Elute fractions were collected into a 96-well plate using a 1260 series auto-sample fraction collector. The 96 elute fractions were further combined into 24 fractions according to collection time (e.g. Ax/Cx/Ex/Gx, and Bx/Dx/Fx/Hx, A/B/C/D/E/F/G/H represents column, x represents row 1 through row 12) for LC/MS/MS analysis.

Nanospray LC/MS/MS analysis and database search performed by Poochon Scientific
LC/MS/MS analysis was carried out using a Thermo Scientific Q-Exactive hybrid Quadrupole-Orbitrap Mass Spectrometer and a Thermo Dionex UltiMate 3000 RSLCnano System. Each peptide fraction from a set of 24 fractions was loaded onto a peptide trap cartridge at a flow rate of 5 μL/min. Trapped peptides were eluted onto a reversed-phase 20 cm C18 PicoFrit column (New Objective, Woburn, MA) using a linear gradient of acetonitrile (3-36%) in 0.1% formic acid. The elution duration was 110 min at a flow rate of 0.3 μL/min. Eluted peptides from the PicoFrit column were ionized and sprayed into the mass spectrometer, using a Nanospray Flex Ion Source ES071 (Thermo) under the following settings: spray voltage, 1.8 kV, Capillary temperature, 250°C. 24 fractions were analyzed sequentially. The Q Exactive instrument was operated in the data dependent mode to automatically switch between full scan MS and MS/MS acquisition. Survey full scan MS spectra (m/z 300–1800) was acquired in the Orbitrap with 70,000 resolutions (m/z 200) after accumulation of ions to a 1 × 10^6 target value based on predictive automatic gain control (AGC). Dynamic exclusion was set to 20 s. The 15 most intense multiply charged ions (z ≥ 2) were sequentially isolated and fragmented in the octopole collision cell by higher-energy collisional dissociation (HCD) using normalized HCD collision energy 28% with an AGC target 1×10^5 and a maximal injection time of 100 ms at 17,500 resolutions. MS Raw data files (24 files from 24 fractions) were searched against the Rattus norvegicus (Rat) protein sequences database obtained from UniprotKB website using Proteome Discoverer 1.4 software (Thermo, San Jose, CA) based on the SEQUEST and percolator algorithms. False positive discovery rates (FDR) was set on 5%. A Proteome Discoverer Report was generated containing all assembled proteins with peptides sequences and peptide spectrum match counts (PSM#) and TMT-tag based quantification ratio.
TMT-tag based quantification was used to determine the relative abundance of proteins identified from each set of 11 samples using one TMT-10plex. The TMT-Tag-131 was used as the common denominator for calculation of the ratio (e.g. A1-TMT-tag-126 versus sample 11-Tag131). Relative abundance of proteins was normalized based on the sum of ratios (Figure 15 and Figure 16).

**Figure 15. Poochon Scientific Schematic of Experimental Workflow.** One TMT set labeled 11 samples. Procedures included preparation of lysates, trypsin digestion, TMT-Il plex of
labeling of tryptic peptides, fractionation of labeled peptides by basic reverse-phase UHPLC, nano-LC-MS/MS analysis on a Q-Exactive mass spectrometer, database search, normalization and data analysis.

Figure 16. Poochon Scientific Schematic of Experimental Workflow. One TMT set labeled 11 samples. Procedures included preparation of lysates, trypsin digestion, TMT-II plex of labeling of tryptic peptides, fractionation of labeled peptides by basic reverse-phase UHPLC, nano-LC-MS/MS analysis on a Q-Exactive mass spectrometer, database search, normalization and data analysis.

Analysis performed by Jennifer Bradley

Kyoto Encyclopedia of Genes and Genomes (KEGG), a collection of genomes and biological pathways, was used to map pathways from proteins identified. NCBI accession numbers (136) (4,997) were converted to Kegg (137) (3,195). One KEGG pathway was identified to have been significantly regulated by CA/CPR (138). NCBI terms were converted to Go terms by Biological DataBase network with p values obtained by Poochon Scientific for Revigo analysis. Revigo uses a clustering algorithm to sort GO terms by similarity into similar biological processes (139).
IV. *In vitro*-WIN55

Yanyan Wang trained Jennifer Bradley on *in vitro* techniques, Jennifer Bradley performed cell culture with reagents prepared by Yanyan Wang, ELISA, analyzed all data and drafted SCCM 2020 abstract. Huiping Zhou and Wanchun Tang reviewed data and abstract drafts. Mouse RAW 264.7 macrophage cells (ATCC, Rockville MD, USA) were plated into 60mm dishes with a density of 10*10^5 cells/dish and incubated with DMEM containing 10% FBS, 1%PS overnight. Cell media was then changed to DMEM containing 1% FBS, 1%PS, and incubated for 4hrs (140, 141). They were then pretreated with WIN55 (5 μM) (142) for 2 hrs, then treated with LPS (12.5 ng/mL) for 6hrs and 24 hrs. At the end of treatment, culture media was collected and centrifuged at 14,000 x rpm for 1 min (143). Media protein levels of TNFα, IL6, and IL1β were quantified using commercial enzyme-linked immunosorbent assays (ELISAs) (R&D Systems, Minneapolis, MN, USA) (144). Concentrations were expressed as pg/mL.

V. *In vivo*-WIN55

Yan Xiao, Jadd Khoraki and Jennifer Bradley performed surgical technique. Jennifer Bradley performed ELISA and analyzed all dissertation data and Wanchun Tang reviewed. This study was approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University. Animal care and handling were in accordance with the Guide for the Care and Use of Laboratory Animals and the ARRIVE guidelines.

**Animal Preparation**

Male Sprague Dawley rats, weighing between 450g and 550g were anesthetized by intraperitoneal injection of pentobarbital (45 mg/kg). The trachea was orally intubated with a 14-gauge cannula (Abbocath- T; Abbott Hospital Products Division, North Chicago, IL). ETCO₂
was continuously monitored with a side-stream infrared CO\textsubscript{2} analyzer (Capstar-100 Carbon Dioxide Analyzer; CWE, Ardmore, PA). A conventional lead II ECG was monitored continuously. A PE-50 catheter (Becton Dickinson, Franklin Lakes, NJ, USA) inserted into the descending aorta measured arterial pressure and was utilized for blood withdrawal. A thermocouple microprobe (9030-12-D-30, Columbus instruments, Columbus, OH, USA) inserted into the left femoral vein measured blood temperature. Another PE-50 catheter advanced into the right atrium measured right atrial pressure. A 3F catheter (Model C-PMS-301J; Cook Critical Care, Bloomington, IN) advanced into the right atrium was utilized to advance a pre-curved guidewire into the right ventricle to induce VF. Another PE-50 catheter inserted into the right femoral vein was utilized for drug infusion \textit{(Figure 17)}. All catheters were flushed intermittently with saline containing 2.5 IU/mL of crystalline bovine heparin (145). Aortic blood temperature was maintained at 37°C ± 0.5°C by a heated surgical board. ECG, aortic and right atrial pressures, ETCO\textsubscript{2}, and blood temperature were continuously recorded on a personal computer–based data acquisition system supported by WINDAQ software (DATAQ, Akron, OH).
Figure 17. *In vivo*-Study Design
**In vivo-WIN55 Experimental Protocol**

**Experimental Procedures**

Animals were randomized into 2 groups (Figure 18) : 1) 2% Tween 80 (VF 6 min + CPR 8 min, defibrillation and ROSC followed by infusion) (n=3), 2) SR141716A+WIN55 (IM Administration of SR141716A (Figure 19) (5 mg/kg, dissolved in 0.1 mL dimethylsulfoxide) before VF 6 min + CPR 8 min, defibrillation and ROSC followed by infusion) (n=6). At 5 minutes after ROSC, either WIN55 (1 mg/kg/h) or vehicle (2% Tween-80 in 0.9% NaCl solution) was administered by continuous intravenous infusion with a syringe pump (Genie Touch; Kent Scientific Corporation) for 4 hours at a rate of 1.4 mL/kg/h (114). Mechanical ventilation was established at a tidal volume of 0.60 mL/100g of body weight, a frequency of 100 breaths/min, and FiO2 of 1.0. VF was then induced with a progressive increase in 60-Hz current to a maximum of 3.5 mA delivered to the right ventricular endocardium. Current flow continued for 3 min to prevent spontaneous defibrillation. After 6 min of untreated VF,
precordial chest compressions, together with mechanical ventilation, were initiated using a pneumatically driven mechanical chest compressor. Precordial chest compressions were maintained at a rate of 200/min and synchronized to provide a compression/ventilation ratio of 2:1 with equal compression-relaxation for 8 min. Defibrillation was attempted with up to three 4-J counter shocks. ROSC was defined as the return of supraventricular rhythm with a MAP above 50 mm Hg for 5 min.

Figure 19. SR141716A is an antagonist for CB₁ (111)

Measurements

Hemodynamics and myocardial function

Electrocardiogram, aortic and right atrial pressures, blood temperature, and ETCO₂ values were continuously recorded on a personal computer-based data-acquisition system supported by WINDAQ software (DATAQ, Akron, OH). At baseline, 2 and 4 hours after ROSC, EF, CO, and myocardial performance index (MPI) were measured by echocardiography (HD11XE; Philips
Medical Systems, Eindhoven, Netherlands) with a 12.5 Hz transducer. EF and CO are adopted to estimate the myocardial contractility; MPI is adopted to estimate left ventricular diastolic function. The MPI, which combines time intervals related to systolic and diastolic functions reflecting the global cardiac function, is also calculated using the formula \((a − b)/b\), where 
\(a\) = mitral closure-to-opening interval (time interval from cessation to onset of mitral inflow) and 
\(b\) = ET (aortic flow ejection time, obtained at the left ventricle outflow tract) (145).

**ELISA Analysis**

One ml blood samples were collected at baseline, 2 and 4 hours after ROSC. After centrifugation (2,100×g, 10 min, 4°C) (146), plasma was removed and stored at −80°C for further ELISA analysis. Protein levels of TNFα, IL6, IL10 (R&D Systems, Minneapolis, MN, USA) S100A8 and cardiac troponin I (TNNI3) (LifeSpan BioSciences, Seattle, WA, USA) were quantified using commercial ELISA kits. ELISA measurement was performed following manufacturer’s instructions.

**VI. Statistical Analysis**

GraphPad PRISM version 9.0 for Windows (GraphPad Software Inc., San Diego, CA) was used to conduct analyses. Data are expressed as mean ± standard deviation (SD). Differences between greater than three groups were compared using a one-way analysis of variance (ANOVA) (Tukey or Bonferonni test for multiple comparisons). When only two groups were present, an unpaired student’s t-test was conducted. A p-value of <0.05 was considered statistically significant.
CHAPTER 3: Cerebral and myocardial mitochondrial injury differ in a rat model of cardiac arrest and cardiopulmonary resuscitation

RATIONALE

Mitochondria are both targets and sources of damage during ischemia and reperfusion (22, 147). Following ischemia and reperfusion, mitochondrial dysfunction involves the increased production of reactive oxygen species (ROS), alteration of electron transfer activity, opening of the mitochondrial permeability transition pore (MPTP) and cytochrome c release (148-155). Ischemia damages the electron transport chain (ETC) (156) and decreases the rate of oxidative phosphorylation (OXPHOS) (157, 158). However, little is known regarding the effects of VF and CPR consistent with salvage by resuscitation on brain and heart mitochondrial function.

We hypothesize that mitochondrial damage differs between the brain and heart. Brain mitochondria are more vulnerable to ischemia and suffer reperfusion injury in addition to ischemic alterations, resulting in diminished overall mitochondrial respiration following resuscitation (159). The purpose of this study was to measure mitochondrial function following cardiac arrest (CA) with and without cardiopulmonary resuscitation (CPR) using OXPHOS, ETC enzyme activity and calcium retention capacity (CRC) as an index of susceptibility to MPTP opening.

RESULTS

Body weight, blood temperature, ETCO$_2$ and CPP during CPR were not different between VF+CPR and ROSC 1hr (Table 2). The maximal rate of OXPHOS was measured stimulated by 2 mM ADP with glutamate as a complex I substrate. Oxidative phosphorylation was decreased by CA in brain and remained depressed through CPR and ROSC (Figure 20). Cardiac mitochondria were less susceptible to injury, with preserved OXPHOS until the reperfusion of
ROSC in SSM (Figure 21) and preserved function throughout in IFM (Figure 22). As previously described, SSM were more susceptible to injury than IFM (127, 150, 160). Inhibition of complex I activity is one of the earliest alterations in mitochondrial function due to ischemia (161).

Maximal rate of OXPHOS stimulated by 2 mM ADP with TMPD-ascorbate as a complex IV substrate was no different in brain compared to heart mitochondria (Table 3).

<table>
<thead>
<tr>
<th>Variables</th>
<th>VF+CPR</th>
<th>ROSC 1hr</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body Weight (g)</td>
<td>487.8±19.2</td>
<td>487.2±6.4</td>
</tr>
<tr>
<td>Blood temperature (°C)</td>
<td>36.7±0.4</td>
<td>36.7±0.3</td>
</tr>
<tr>
<td>ETCO₂ (mmHg)</td>
<td>25.5±3.1</td>
<td>25.9±4.9</td>
</tr>
<tr>
<td>CPP (mmHg)</td>
<td>27±3</td>
<td>27.5±2.9</td>
</tr>
</tbody>
</table>

Mean ± SD, Unpaired t test, p>0.05 vs VF+CPR N=6 in each group.
Figure 20. **BM oxidative phosphorylation with glutamate as a complex I substrate** - Oxygen consumption in mitochondria was measured using a Clark-type oxygen electrode at 30°C. Mitochondria were incubated in a solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM KH2PO4, and 1 mg/ml bovine serum albumin, at pH 7.4. After depletion of endogenous substrates by addition of ADP, glutamate (complex I substrate) was added as an electron donor. Oxidative phosphorylation with glutamate as a complex I substrate was decreased by cardiac arrest in brain, and remained depressed through cardiopulmonary resuscitation. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group. My contribution (a) design of the experiments (c) Analysis of the data.
Figure 21. SSM oxidative phosphorylation with glutamate as a complex I substrate- Oxygen consumption in mitochondria was measured using a Clark-type oxygen electrode at 30°C. Mitochondria were incubated in a solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM KH2PO4, and 1 mg/ml bovine serum albumin, at pH 7.4. After depletion of endogenous substrates by addition of ADP, glutamate (complex I substrate) was added as an electron donor. Oxidative phosphorylation with glutamate as a complex I substrate preserved OXPHOS until the reperfusion of ROSC in SSM. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group. My contribution (a) design of the experiments (c) Analysis of the data.
Figure 22. IFM oxidative phosphorylation with glutamate as a complex I substrate- Oxygen consumption in mitochondria was measured using a Clark-type oxygen electrode at 30°C. Mitochondria were incubated in a solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM KH2PO4, and 1 mg/ml bovine serum albumin, at pH 7.4. After depletion of endogenous substrates by addition of ADP, glutamate (complex I substrate) was added as an electron donor. Oxidative phosphorylation with glutamate as a complex I substrate preserved OXPHOS throughout in IFM. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group. My contribution (a) design of the experiments (c) Analysis of the data.
Table 3. Mean Percent Change of Rate of oxidative phosphorylation in brain and heart mitochondria using TMPD as complex IV substrate.

<table>
<thead>
<tr>
<th>2mM ADP</th>
<th>BM</th>
<th>SSM</th>
<th>IFM</th>
</tr>
</thead>
<tbody>
<tr>
<td>VF</td>
<td>Down 38±37.3</td>
<td>Down 28±14.3</td>
<td>Down 23±15.8</td>
</tr>
<tr>
<td>VF+CPR</td>
<td>Down 21±9.4</td>
<td>Down 17±10.2</td>
<td>Up 33±17.3</td>
</tr>
<tr>
<td>ROSC 1hr</td>
<td>Down 24±12</td>
<td>Down 33±29.7</td>
<td>Down 39±23.7</td>
</tr>
</tbody>
</table>

Mean ± SD, p>0.05 vs Sham rates: BM 2672±666.8; SSM 5844±1539.6; IFM 3968±1257.6 nA/min/mg mitochondrial protein; N=6 in each group. Oxygen consumption in mitochondria was measured using a Clark-type oxygen electrode at 30°C. Mitochondria were incubated in a solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM KH2PO4, and 1 mg/ml bovine serum albumin, at pH 7.4. After depletion of endogenous substrates by addition of ADP, TMPD-ascorbate (complex IV substrate) was added as an electron donor.

Enzyme activity of ETC complexes was measured to identify the primary sites most affected by ischemia within the ETC. CA resulted in sustained damage to complex I in brain mitochondria (Figure 23). NADH:ferricyanide oxidoreductase activity decreased following ROSC, suggesting that reperfusion caused damage to the NADH oxidase portion of the complex (Figure 24). In contrast, complexes II and III remained unaltered (Table 4). In this rat model of CA and CPR, brain complex I is more vulnerable to damage during ischemia and reperfusion than complex II or complex III. Complex I in brain is also more susceptible to damage than complex I in heart.
Figure 23. BM enzyme activity confirmation of Complex I damage. CA resulted in sustained damage to complex I in brain mitochondria. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=5 in each group. My contribution (a) design of the experiments (c) Analysis of the data.
**Figure 24. BM enzyme activity of NADH:ferricyanide oxidoreductase**-decreased following return of spontaneous circulation. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=5 in each group. My contribution (a) design of the experiments (c) Analysis of the data.
Table 4. Brain and heart mitochondria Electron Transport Chain Results.

<table>
<thead>
<tr>
<th></th>
<th>Complex II</th>
<th>Complex III</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BM</td>
<td>SSM</td>
</tr>
<tr>
<td>SHAM</td>
<td>274.8±69.3</td>
<td>101.4±47.9</td>
</tr>
<tr>
<td>VF</td>
<td>230.2±67.9</td>
<td>--</td>
</tr>
<tr>
<td>VF+CPR</td>
<td>223±39.6</td>
<td>70±10.4</td>
</tr>
<tr>
<td>ROSC 1hr</td>
<td>178±70.1</td>
<td>89.6±14</td>
</tr>
</tbody>
</table>

|                  | BM         | SSM         | IFM         |
|------------------|------------|-------------|
| SHAM             | 3572±739.4 | 4128.2±1251.7 | 4974±554.3 |
| VF               | 2896.4±672.5 | --        | --          |
| VF+CPR           | 3039.8±365.8 | 1869.2±515* | 4722±1065.7 |
| ROSC 1hr         | 3043±698.3 | 2501.6±1543.9 | 4045.6±581.5 |

Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham. Enzyme activity is mU/mg mitochondrial protein. N=5 in each group.

In the heart, VF+CPR decreased complex I activity in SSM and remained low during the first hour of ROSC (Figure 25). NADH:ferricyanide oxidoreductase activity was decreased concomitant with the decrease in complex I activity, suggesting that the site of damage is in the NADH oxidase portion of the complex (Figure 26). In contrast, IFM were relatively free of damage with a non-significant trend of decreased complex I activity (Figure 27). Complexes II and III did not sustain damage in IFM (Table 4).
Figure 25. SSM enzyme activity confirmation of Complex I damage. VF+CPR decreased complex I activity. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=5 in each group. My contribution (a) design of the experiments (c) Analysis of the data.
Figure 26. SSM enzyme activity of NADH:ferricyanide oxidoreductase-decreased NFR activity. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=5 in each group. My contribution (a) design of the experiments (c) Analysis of the data.
Figure 27. IFM enzyme activity of Complex I. Mean ± SD, One-way ANOVA, Tukey Post-hoc p>0.05 vs Sham N=5 in each group. My contribution (a) design of the experiments (c) Analysis of the data.

Calcium retention capacity (CRC) in brain decreased rapidly and was abnormal throughout CA and CPR (Figure 28), in contrast to heart CRC that only decreased following ROSC in both SSM and IFM (Figure 29 and Figure 30). Thus, brain mitochondria are more susceptible to MPTP opening compared to heart mitochondria. Furthermore, an increased susceptibility to MPTP opening is already evident in brain mitochondria during the initial period of CA.
Figure 28. BM calcium retention capacity (CRC)-measured as an index of susceptibility to MPTP opening. CRC in brain rapidly decreased, and was abnormal throughout CA and CPR. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group. My contribution (a) design of the experiments (c) Analysis of the data.
Figure 29. SSM calcium retention capacity (CRC)-measured as an index of susceptibility to MPTP opening. Heart mitochondria only decreased following ROSC. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group. My contribution (a) design of the experiments (c) Analysis of the data.
**Figure 30. IFM calcium retention capacity (CRC)–measured as an index of susceptibility to MPTP opening. Heart mitochondria only decreased following ROSC. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group. My contribution (a) design of the experiments (c) Analysis of the data.**

**DISCUSSION**

Our experimental CA/CPR (145, 162, 163) model indicates that mitochondrial damage is different between rat brain and heart. Brain mitochondria are more sensitive to global ischemia. Heart SSM are minimally damaged whereas IFM remain intact. In contrast, mitochondrial OXPHOS and ETC indicate that complex I is markedly decreased in brain. This is in line with Borutaite et al. reporting a decrease in complex I activity after 20-25min of global no-flow ischemia (161). Alleviation of complex I injury may be an important therapeutic target to reduce brain injury during CA and CPR. Currently, no pharmacological treatment has been approved for
neuroprotection after CA (9). Donnino et al’s characterization of mitochondrial injury after cardiac arrest (COMICA) clinical trial demonstrated mixed results with mitochondrial injury markers post-arrest. Pathways in humans remain incompletely characterized and need to be studied further (34).

OXPHOS, with glutamate is used to assess the response of intact mitochondria to ischemia (164). Ischemia leads to progressive injury to the ETC (22, 127) and ischemic mitochondrial damage occurs more rapidly in SSM, which are located beneath the plasma membrane, than in IFM, which are located between the myofibrils (127). SSM were more susceptible to injury than IFM, which is consistent with previous studies (127, 150, 160). SSM and IFM injury induced by 8 min of CA did not progress despite markedly reduced blood flow and oxygen supply during 8 min of CPR. Results are less severe than studies of more prolonged ischemia (15, 131, 150). Myocardial mitochondria show a markedly increased susceptibility to opening of the MPTP following a more robust reperfusion resulting from one hour of ROSC. There is a significant decrease in mitochondrial function following 25 min of stop-flow myocardial ischemia (129). CPR is sufficient to interrupt or slow the ongoing ischemic insult imposed on myocardial mitochondria, and possibly extends the period of mitochondrial viability during early stages of CA.

The rate of OXPHOS was markedly decreased in brain mitochondria oxidizing complex I substrate (Figure 20). A complex I defect occurs during cerebral ischemia or CA. This was confirmed by enzyme activity measurement (Figure 23). Furthermore, the activity of NADH:ferricyanide oxidoreductase (NFR) was decreased (127) (Figure 24). Ferricyanide is an artificial electron acceptor that is reduced by the flavin mononucleotide cofactor in the NADH dehydrogenase component of complex I (165). Complex I activity decreases during ischemia in
cardiac mitochondria due to a decrease in the NADH dehydrogenase component likely due to loss of the flavin mononucleotide coenzyme (156, 166-168). Damage to the NADH dehydrogenase component of complex I can increase electron leak and ROS production, contributing to brain damage after CA (168). Reperfusion of ischemic brain also leads to massive generation of ROS (169). Activated microglia convert into a pro-inflammatory (M1) phenotype that obtains macrophage-like properties (such as antigen presentation) and generates several pro-inflammatory mediators (such as IL1 β, TNFα, and ROS) that can disrupt the blood brain barrier (BBB) (9). Generation of ROS, including from complex I itself, can lead to complex I damage (125, 129, 169). Development of ischemic acidosis during CA might also facilitate flavoprotein dissociation, hindering electron transfer and impairing complex I activity (15).

Consistent with the decrease in NFR, ischemia induced loss of FMN may contribute (170). Ischemia also damages complex I at sites more distal in the path of electron flow at iron sulfur centers, including immediately proximal to the quinol binding site (129, 171). Complex I also undergoes a conformational change from an active form to a “de-active” form (170). However, the de-active form of complex I should be reactivated under conditions of the ETC assay. Whether these potential contributing factors contribute to the beneficial effects of CPR remains to be explored. In general, brain mitochondrial dysfunction following ischemia is associated with impaired complex I activity.

Mitochondrial dysfunction after resuscitation from CA due to impaired electron transport through the respiratory complexes of the ETC leading to decreased rates of OXPHOS is poorly characterized in patients who achieve ROSC. ETC dysfunction reduces mitochondrial membrane potential. Impaired OXPHOS leads to decreased generation of high energy phosphates. Direct damage to mitochondria leads to diminished electron flow and increased ROS generation,
favoring oxidative tissue injury. Damage to the mitochondrial inner membrane leads to decreased membrane potential and favors cytochrome c release into the cytosol, which activates cell death (14). Mitochondrial defects are associated with reduced ATP generation, metabolic failure, altered signaling pathways, and induction of apoptosis.

Susceptibility of MPTP opening has been implicated as a key mechanism underlying both necrotic and apoptotic cell death during ischemia and reperfusion (172-174). Kristian et al. report mitochondria energized with either electron transport complex I or complex II substrates within an acidic environment promote permeability transition pore opening (175). MPTP opening increases the permeability of both inner and outer mitochondrial membranes. Because of MPTP opening, solutes with a molecular mass of up to 1,500 Da non-selectively diffuse across the mitochondrial inner membrane, leading to mitochondrial depolarization, uncoupling of OXPHOS, and large amplitude swelling, leading to ATP depletion and cell death (174). The effectiveness of mPTP inhibitors to protect the myocardium has not been observed in clinical trials of acute myocardial infarction (176). However, neuronal cyclophilin D represents a promising therapeutic target for Alzheimer’s disease (177). The development of nopeptidic small molecule inhibitors of cyclophilin D could be a promising approach for cardiac arrest as our study demonstrates a markedly increased susceptibility to MPTP opening within brain mitochondria. This occurs during the initial period of ischemia due to CA and persists throughout the course of CPR, including resuscitation and ROSC. In contrast, the susceptibility of cardiac MPTP opening increases during ROSC. Therefore, brain MPTP susceptibility during ischemia is different than in heart (178). Briston et al. reports complex I-driven respiration is reduced after MPTP opening (179). Cardiac mitochondria are more resistant to damage during ischemia. However, increased susceptibility to MPTP opening occurred during ROSC, likely as a
result of calcium overload associated with reperfusion (180, 181). Therefore, reperfusion injury affects heart mitochondria even after short durations of ischemia.

A complex I targeted therapeutic could also potentially ameliorate brain mitochondrial dysfunction after cardiac arrest. Preservation of complex I activity could potentially provide better clinical outcomes of survival with good neurological function (currently only 8.2%) and survival to hospital discharge (currently 10.4%) (1). Further research is necessary regarding mechanism among cardiac arrest victims. In a middle cerebral artery occlusion (MCAO) rat model, decreased activity of Complex I, III, and IV after ischemia/reperfusion injury contributed to decreased mitochondrial function, which was restored with a low-dose of methylene blue (MB) (182). The neuroprotective role of MB in cerebral ischemia has been suggested to be caused by increased mitophagy and maintenance of mitochondrial membrane potential (182).

Therapeutic Hypothermia is a standard intervention to improve outcomes following cardiac arrest and cardiopulmonary resuscitation. Although therapeutic hypothermia can preserve energy stores, current work also suggests that reactive oxygen species production is also decreased (183, 184). This is plausible, since hypothermia decreases rates of electron transport. Transient, partial blockade of electron transport during early reperfusion protects the heart (125, 185, 186). Hypothermia slows electron transport and reactive oxygen species generation in the intact heart with a similar profile to that of blockade of electron transport (187). Thus, there is a premise for protection of the brain and heart following cardiac arrest by therapeutic hypothermia (WIN55 via CB1).

Complex I preservation would mitigate lowered levels of ATP, dramatic shifts in calcium concentration and cell swelling. Our study demonstrates the brain is most reliant on mitochondrial bioenergetics (188). It takes less ischemia/reperfusion to cause dysfunction in the
brain compared to the heart. Reperfusion of ischemic brain will lead to massive generation of free radicals such as ROS and activation of several signaling pathways (9). Our findings suggest that CPR is able to preserve heart mitochondrial function and viability longer than that of brain during ongoing global ischemia despite low blood flow and oxygen delivery. A metabolic phase of cardiac arrest (188) occurs earlier than reported previously. Therefore, preservation of brain complex I activity during CA will likely continue to emerge as a critical therapeutic target. WIN55 could be a pharmacologic tool as it has been shown to decrease brain injury reducing both delayed cell death and glial damage (38).

CONCLUSIONS

Brain mitochondria are more sensitive to global ischemia compared to heart mitochondria. Additionally, complex I is the most sensitive ETC complex to ischemic injury and its activity determines rate of OXPHOS following CA and resuscitation. Preservation of brain mitochondrial activity and function during CA may enhance outcomes and recovery. Future work is needed to improve current clinical resuscitation success rates by addressing an early therapeutic target preserving complex I activity during CA.

LIMITATIONS

Our generalized use of brain and heart within this dissertation are the cerebrum and whole heart, which is a limitation within the current study. Future studies are needed to address the following: visualization of structural damage using electron microscopy, measurement of reactive oxygen species production, measurement of pro-inflammatory mediators and the use of interventions to enhance complex I activity to determine beneficial effects. Analysis of mitochondria with a treatment group of WIN55 would further enhance the mechanism of this pharmacologic tool.
CHAPTER 4: Quantitative mass spectrometric analysis of cardiac whole tissue lysate proteome changes from our rat cardiac arrest and cardiopulmonary resuscitation model

RATIONALE

For aerobic cells ischemia is a critical change in the oxygen demand to delivery ratio (189). CA is characterized by severe and generalized ischemia that persists during resuscitation efforts and reverses only after ROSC (2). Ischemia causes reperfusion injury. In general, reperfusion injury is proportional to the magnitude of the preceding period of ischemia. All tissues can withstand variably short periods of ischemia that do not produce detectable functional deficits or evidence of injury. However, once a critical duration of ischemia is exceeded, which varies by cell type and organ, cell injury and/or death ensues (190). Within the usual timeframe of CA and resuscitation, ischemic injury is most severe in organs with high metabolic demands, such as the brain and heart (2).

Studies have shown that S100A8/A9 levels positively correlate with risk of acute myocardial infarction (191, 192). Additionally, site-specific measurements of S100A8/A9 in patients with acute coronary syndrome demonstrate that S100A8/A9 is markedly more elevated at the site of coronary occlusion compared to systemic circulation (193). Further support of this finding, immunostaining, reveals S100A8/A9 is specifically expressed in neutrophils and macrophages infiltrating the myocardium post-infarction (192). Together, these studies demonstrate S100A8/A9 is a major player in local inflammation caused by acute cardiovascular events.

We hypothesize that S100A8/A9 expression increases within heart whole tissue lysate after CA and CPR. The purpose of this study was to measure proteome changes following CA using quantitative mass spectrometric analysis.
RESULTS

Quantification of total protein concentration of supernatant was determined by a BCA™ Protein Assay (Figure 31). 4,997 proteins (Sham 3) were quantitatively identified across 3 groups of 11 samples using one TMT10plex Isobaric Label Reagent Set plus TMT11-131C Label Reagent. 239 of the 4,997 proteins identified to be differentially expressed (fold change >=1.25, p<0.05, n=3 or 4) upon CPR compared to Sham+Norm (Figure 32). 104 proteins changed by at least 25% highlighted in purple (fold change >=1.25, p<0.05). Housekeeping proteins are not changed. Another volcano plot of the 171 proteins changed <0.75 and >1.25 was compared between CPR and Sham+Norm (Figure 33).

Four proteins that were most significant were Fibrinogen gamma chain precursor (functions in hemostasis as one primary component of blood clots and functions during the early stages of wound repair to guide cell migration during re-epithelialization) (194), Parvalbumin alpha (in muscle it is thought to be involved in relaxation after contraction) (195), G-protein coupled receptor (involved in cell recognition and communication processes) and Transketolase-like protein 2 isoform X1(protein has several cofactor biding sites including calcium binding) (196). These four proteins with the greatest change in expression are noted, however, we focused on S100A8 and S100A9 due to Li et al. connecting S100A8/A9 signaling with mitochondrial complex I dysfunction and cardiomyocyte death in response to myocardial ischemia reperfusion injury (132).
Figure 31. Supernatant BCA Assay. Mean ± SD, One-way ANOVA, Tukey Post-hoc p > 0.05 vs Norm N=3 (Norm) or 4 (Sham and CPR). Equal protein loading allows for comparison of TMT tags. My contribution (a) design of the experiments (c) Re-analysis of the data provided by Poochon Scientific.
Figure 32. Volcano Plot 4,997 Proteins Identified by Poochon Scientific. My contribution (a) design of the experiments (c) Re-analysis of the data provided by Poochon Scientific.
**Figure 33. Volcano Plot CPR/Norm+Sham Ratio <0.75 and >1.25**

Proteins Identified. Accession Numbers 61098186-Fibrinogen gamma chain precursor [Rattus norvegicus], 11968064-Parvalbumin alpha [Rattus norvegicus], 60389876- G-protein coupled receptor and 564388869- Transketolase-like protein 2 isoform X1 [Rattus norvegicus]. Pink are S100A8 and S100A9[Rattus norvegicus]. My contribution (a) design of the experiments (c) Re-analysis of the data provided by Poochon Scientific.

Kyoto Encyclopedia of Genes and Genomes (KEGG), a collection of genomes and biological pathways, was used to map pathways from the 4,997 proteins identified by Poochon Scientific (3,195 Kegg were able to be converted from the 4,997 NCBI). Biological pathways such as oxidative phosphorylation (*Figure 34*), complement and coagulation cascades (*Figure 35*), toll-like receptor signaling (*Figure 36*) and chemokine signaling were mapped (*Figure 37*). The complement and coagulation cascade was identified to have multiple proteins expressed after CA and CPR (64 Kegg were able to be converted from the 104 proteins >1.25) (*Figure 38*). Genes highlighted in red indicate presence.
Figure 34. 3,195 converted Kegg proteins **rno00190** Oxidative phosphorylation—Rattus norvegicus (rat) (81). Red indicates gene presence. My contribution (a) design of the experiments (c) Kegg pathway analysis of data provided by Poochon Scientific.
Figure 35. 3,195 converted Kegg proteins *rno04610* Complement and coagulation cascades- Rattus norvegicus (rat) (36). Red indicates gene presence. (a) design of the experiments (c) Kegg pathway analysis of data provided by Poochon Scientific.
Figure 36. 3,195 converted Kegg proteins **rno04620** Toll-like receptor signaling pathway-Rattus norvegicus (rat) (16). Red indicates gene presence. (a) design of the experiments (c) Kegg pathway analysis of data provided by Poochon Scientific.
Figure 37. 3,195 converted Kegg proteins `rno04062` Chemokine signaling pathway- Rattus norvegicus (rat) (37). Red indicates gene presence. (a) design of the experiments (c) Kegg pathway analysis of data provided by Poochon Scientific.
Figure 38. 64 converted Kegg proteins (CPR/Sham+Norm Ratio -log10 p>1.25) rno04610 Complement and coagulation cascades-Rattus norvegicus (rat) (13). Red indicates gene presence. (a) design of the experiments (c) Kegg pathway analysis of data provided by Poochon Scientific.

A scatter plot for the CA and CPR data that was used to create the KEGG pathway in Figure 38 was generated through multidimensional scaling. Similar GO terms are grouped closer together in the plot based on similar semantics (Figure 39). Color of biological processes clusters corresponds to the p-value input provided by Poochon Scientific. Biological processes that are most enriched and clustered together are pathways involved with ischemia reperfusion injury.
DISCUSSION

CPR/Sham+Norm ratio DAVID 6.8 analysis showed S100A8/A9 expression increased (CPR avg higher than Sham+Norm avg). Intracellular S100A8/A9 is best known for the ability to regulate transendothelial migration of leukocytes (73, 197). Both are constitutively expressed in neutrophils, monocytes and dendritic cells. However, they can also be intensely upregulated upon the onset of trauma, infection, heat, stress and other inflammatory processes (69).
Extracellular S100A8/A9 is a damage associated molecular pattern after being released from
damaged or activated cells, therefore increased expression seen in heart tissue lysates obtained at
ROSC is due to ischemia/reperfusion injury from CA.

Relative cardiac S100A8 and S100A9 mRNA expression in mice subjected to myocardial
IR procedures had peak S100A8/A9 mRNA expression at 6hrs in the heart. Proteomic analysis
from Poochon Scientific was performed on heart tissue lysate collected at ROSC (no more than
30 minutes from VF). S100A8/A9 is critical for IR induced myocardial death, the sequelae of
adverse cardiac remodeling, and heart failure (132). The release of S100A8 and S100A9 can
induce C3/CFB complement activation and secretion of multiple cytokines in inflammatory cells
to sustain and exacerbate inflammation (69). Therefore, they control early stages of inflammation
for cardiac IR injury after CA. Inhibition of S100A8/A9 activity during CA could be a potential
therapeutic target.

CONCLUSIONS

S100A8 and S100A9 have promising potential as new biomarkers for cardiovascular
inflammation. Inhibition of S100A8/A9 activity during CA may enhance outcomes and recovery.

LIMITATIONS

Confirmation of proteomic analysis still needs to be done at the tissue level. If we have
tissue available after lipidomic analysis from a collaborator-a future study could include
immunoblot of the brain and heart for S100A8 and S100A9. Du et al. discovered global ischemia
did not alter immunoblot protein levels of S100A8 and S100A9 at 0, 30 and 60 min. In vivo
ischemia for 2hrs resulted in strong S100A8 and S100A9 overexpression (198). Li et al reported
serum S100A8/A9 levels were significantly increased 1 day after percutaneous coronary
intervention in patients with acute myocardial infarction(132). Therefore, future studies could
look at expression of S100A8 and S100A9 peptides in brain and heart and protein levels in plasma at ROSC 4hrs or with a survival model at 24, 48 and 72hrs. Analysis of S100A8/A9 protein expression with a treatment group of WIN55 would further enhance the mechanism of this pharmacologic tool.
CHAPTER 5: Anti-Inflammatory activity of WIN55, 212-2, a non-selective cannabinoid CB1/CB2 receptor agonist in cultured RAW264.7 macrophage cells

RATIONALE

Macrophages are innate immune cells that form the first line of defense against invading pathogens (62). Under different pathophysiologic conditions, activated macrophages are capable of differentiating into phenotypically different states, including the classically activated (M1) and the alternatively activated (M2) (61). M1 macrophages are characterized by the production of pro-inflammatory cytokines, such as IL1, IL6, IL12, TNFα and chemokines, involved in various inflammatory processes (61). They are major producers of TNFα and are also highly responsive to TNFα (62). TNFα is rapidly released after trauma, infection, or exposure to bacterial-derived LPS and has been shown to be one of the most abundant early mediators in inflamed tissue (62).

TLR signals have an important role in regulating macrophage polarization. In particular, the TLR4 ligand LPS promotes macrophage differentiation toward M1 phenotype (61). TNFα has been shown to play a pivotal role in orchestrating the cytokine cascade in many inflammatory diseases and because of this role as a “master-regulator” of inflammatory cytokine production, it has been proposed as a therapeutic target for a number of diseases (62). IL6 is also another pro-inflammatory cytokine secreted by monocytes and macrophages after engagement of Toll-like receptors (TLRs) that promotes inflammatory events (66, 199).

Hao et al. reported oxLDL-induced TNFα expression and ROS generation in RAW 264.7 mouse macrophages is considerably reduced by the synthetic cannabinoid WIN55. Reduced TNFα expression and ROS production is mainly via the CB2 receptor, and partially linked with the CB1 receptor. MAPK and NF-kappa β are inhibited by WIN55 activated CB1/CB2 receptor signaling, suggesting their involvement in the attenuation of TNFα expression and ROS generation (200). Therefore, we hypothesize that pre-treatment with WIN55 will have anti-
inflammatory effects against LPS induced pro-inflammatory mediators TNFα, IL6 and IL1β. The purpose of this study was to measure LPS induced TNFα, IL6 and IL1β protein expression with and without pre-treatment of WIN55 in mouse RAW 264.7 macrophages.

RESULTS

TNFα, IL6 and IL1β were all increased following LPS stimulation. Pre-treatment with WIN55 decreased TNF-α (9,206±847 (SD) pg/mL) compared to 6hrs LPS (15,694±2,285 p<0.05) (Figure 40). Pre-treatment with WIN55 also decreased IL6 (7,136±1,238) and IL-1β (89±21) compared to 24hrs LPS (10,318±2,092 and 207±26 p<0.05) (Figure 41 and Figure 42).
Figure 40. Pre-treatment with WIN55 decreased TNFα compared to 6hrs LPS Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs LPS N=3 in each group. My contribution (a) design of the experiments (b) execution of experimental procedure (c) Analysis of the data.
Figure 41. Pre-treatment with WIN55 decreased IL6 compared to 24hrs LPS Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs LPS N=6 in each group. My contribution (a) design of the experiments (b) execution of experimental procedure (c) Analysis of the data.
Figure 42. Pre-treatment with WIN55 decreased IL1β compared to 24hrs LPS. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs LPS; N=6 in each group. My contribution (a) design of the experiments (b) execution of experimental procedure (c) Analysis of the data.
DISCUSSION

LPS is a ligand for TLR 4. It is an endotoxin from the walls of Gram-negative bacteria and is a potent stimulator of inflammatory cytokines in macrophages (201). The initial acute innate immune response to LPS primes the adaptive immune system against further infection (202). Macrophages are the major players in both innate and adaptive inflammatory responses. For this reason, WIN55 was examined for its effect on the expression of TNFα, IL6 and IL1β protein in mouse RAW 264.7 macrophage cells stimulated with LPS. Our macrophage cell culture model indicates that WIN55 inhibited LPS stimulated proinflammatory mediators.

CONCLUSION

WIN55 inhibited LPS induced expression of pro-inflammatory cytokines.

LIMITATIONS

Confirmation of the CB2 receptor as anti-inflammatory still needs to be validated in vitro. There are two different antagonists of CB2 (SR144528 (114) and AM630 (200)) that can be tested to determine if administration blocks the effect of WIN55. Antagonists of CB1 such as SR141716A and AM251 also need to be tested to determine if administration blocks the effect of WIN55. Further studies are also needed using more specific CB2 receptor agonists such as HU308 or JWH-133 (200). Treatment with recombinant S100A8 proteins should also be determined. RAW264.7 macrophage cells should be treated with WIN55 (5 μM) (142) for 2 h, then treated with S100A8 for 6hrs and 24 hrs. S100A8 acts not only as a chemoattractant to macrophages but also as a proinflammatory factor (203). Inhibitors of S100A8 and/or S100A9 should also be tested in vitro. PPARγ expression should also be determined as WIN55 induced PPARγ expression was partially attenuated by AM630 in BEL-7402 cells (204). The effects of WIN55 should also be tested to determine if they are attenuated by PPARγ antagonist GW9662.
(204). PPAR-γ agonists significantly reduced adipose S100A8 mRNA level and plasma S100A8/A9 complex concentrations in obese diabetic mice and human subjects (203). After these effects are determined in RAW264.7 macrophage cells confirmation studies can be conducted in human THP-1 cell lines.
CHAPTER 6: One mechanism of anti-inflammatory activity of cannabinoid agonist WIN55, 212-2 on outcomes of CPR is binding cannabinoid receptor 2 (CB$_2$)

RATIONALE

In non-traumatic CA, common causes are ventricular fibrillation cardiac arrest (VFCA) and asphyxial cardiac arrest (ACA) (205). Recent data from several large population cohorts, covering over 40,000 patients, demonstrate proportions of initial ventricular tachycardia/ventricular fibrillation in the range of 20-25% (13). The 2016 weighted national estimate of emergency department visits with a principal diagnosis of either CA or ventricular fibrillation/flutter was 183,629 patients among the National Emergency Department Sample (1). For this reason, our physiologically relevant VF model developed in 1988 has been used in approximately 70 peer-reviewed publications examining resuscitation aspects including: its physiology and pathophysiology, determinants of resuscitability, pharmacologic interventions, and effects of cell therapies (206). Once we confirmed \textit{in vitro} WIN55 inhibited LPS induced expression of pro-inflammatory cytokines within mouse RAW 264.7 macrophage cells we then explored our experimental \textit{in vivo} CA/CPR (145, 162, 163) rat model.

The Weil Institute has published that infusion of WIN55 decreases body temperature from 37 to 34°C within 4 hours after infusion (114, 207). All animals that received WIN55 survive for more than 72 hours with minimal neurological deficits. Post-resuscitation myocardial function is significantly better than control. We therefore demonstrate the feasibility that therapeutic hypothermia could be induced pharmacologically in settings of CPR without compromising outcomes (207). We further demonstrate that hypothermia effects of WIN55 are completely abolished by selective CB$_1$ receptor antagonist SR141716A (114, 208).
The role of endocannabinoids (eCBs) in the cardiovascular system is paradoxical because both positive and negative effects are observed, particularly in conditions of cardiovascular dysfunction (209). We hypothesize that CA will increase plasma concentrations of TNFα, IL6 and IL10. Therefore, plasma cytokine levels will be elevated after resuscitation. Intramuscular (IM) administration of SR141716A before VF+CPR followed by infusion of WIN55 5 min after ROSC will prohibit the release of inflammatory mediators caused by CA via the CB2 receptor.

The purpose of this study was to measure hemodynamics (electrocardiogram, aortic and right atrial pressures, blood temperature, and ETCO2 values), myocardial function (EF, CO, and MPI) and plasma protein concentrations following CA with and without administration of SR141716A before VF+CPR followed by infusion of WIN55 5 min after ROSC.

RESULTS

Our most recent WIN55 publication and our current studies administered WIN55 5 minutes after ROSC. Blood temperature in WIN55 + Hypothermia decreased progressively from 36.8°C ± 0.2°C to 35.1°C ± 0.5°C during the first hour of infusion and reached 33.3°C ± 0.3°C at 4 hours after infusion (145). Duration of reduced blood temperatures did not have a significant difference between WIN55 + Hypothermia and Hypothermia, which had a similar rate for temperature drop. Due to the use of a heated surgical board, there was no significant reduction in blood temperature in animals with WIN55 + Normothermia which was similar to Normothermia. There was no significant reduction in blood temperature in animals pretreated with SR141716A (Figure 43) (114).
Blood Temperature

Figure 43. Blood temperature was not different between groups. Mean ± SD. Unpaired t test, p>0.05 vs 2% Tween N=3, SR141716A+WIN55 N=6. My contribution (a) design of the experiments (b) execution of experimental procedure (c) Analysis of the data.

MAP and HR in WIN55 + Hypothermia and WIN55 + Normothermia decreased significantly compared with Normothermia at ROSC 1hr, 2hrs, 3hrs, and 4hrs (Figure 44 and Figure 45), while ETCO₂ in WIN55 + Hypothermia increased significantly compared with Normothermia (Figure 46) (145). HR in SR141716A+WIN55 decreased significantly compared to 2% Tween 80 at ROSC 2hrs and 3hrs (Figure 47) while ETCO₂ increased significantly compared with 2% Tween 80 at ROSC 1hr and 4hrs (Figure 48). Administration of SR141716A+WIN55 followed similar hemodynamic changes from previously published results (145).
Figure 44. MAP in WIN55 + Hypothermia and WIN55 + Normothermia decreased significantly compared with Normothermia. Mean ± SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in each group. My contribution (a) design of the experiments (c) Re-analysis of the data.
Figure 45. HR in WIN55 + Hypothermia and WIN55 + Normothermia decreased significantly compared with Normothermia. Mean ± SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in each group. My contribution (a) design of the experiments (c) Re-analysis of the data.

![End Tidal Carbon Dioxide](image)

Figure 46. ETCO₂ in WIN55 + Hypothermia increased significantly compared with Normothermia. Mean ± SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in each group. My contribution (a) design of the experiments (c) Re-analysis of the data.
Figure 47. HR in SR141716A+WIN55 decreased significantly compared to 2% Tween 80 at ROSC 2hrs and 3hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween N=3, SR141716A+WIN55 N=6. My contribution (a) design of the experiments (b) execution of experimental procedure (c) Analysis of the data.
Figure 48. ETCO₂ increased significantly compared with 2% Tween 80 at ROSC 1hr and 4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween N=3, SR141716A+WIN55 N=6. My contribution (a) design of the experiments (b) execution of experimental procedure (c) Analysis of the data.

There was a significant improvement in myocardial function as measured by CO, EF, and MPI, in animals treated with WIN55 + Hypothermia beginning at 1 hour after start of infusion.

WIN55 + Hypothermia significantly improved at ROSC 4hrs compared with Physical Hypothermia (Figure 49, Figure 50 and Figure 51) (145). MPI in SR141716A+WIN55 increased significantly compared with 2% Tween 80 at ROSC 4hrs (Figure 52).
Figure 49. Significant improvement in myocardial function as measured by CO. Mean ± SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in each group. My contribution (a) design of the experiments (c) Re-analysis of the data.

Figure 50. Significant improvement in myocardial function as measured by EF. Mean ± SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in each group. My contribution (a) design of the experiments (c) Re-analysis of the data.
Figure 51. Significant improvement in myocardial function as measured by MPI. Mean ± SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in each group. My contribution (a) design of the experiments (c) Re-analysis of the data.
Myocardial Performance Index

Figure 52. MPI in SR141716A+WIN55 increased significantly compared with 2% Tween 80 at ROSC 4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween N=3, SR141716A+WIN55 N=6. My contribution (a) design of the experiments (b) execution of experimental procedure (c) Analysis of the data.

Figure 53, Figure 54, Figure 55 and Figure 56. IM Administration of SR141716A (Figure 19) (5 mg/kg, dissolved in 0.1 mL dimethylsulfoxide) before VF 6 min + CPR 8 min, defibrillation and ROSC followed by infusion) of WIN55 (1 mg/kg/h) administered by continuous intravenous infusion with a syringe pump (Genie Touch; Kent Scientific Corporation) for 4 hours at a rate of 1.4 mL/kg/h (114) decreased expression in plasma TNFα, IL6, and IL10 at ROSC 4hrs (Figure 53, Figure 54 and Figure 56). Cardiac troponin I and S100A8 protein expression was not different between groups (Figure 55 and Figure 57).
Figure 53. Plasma TNFα. IM Administration of SR141716A before VF+CPR followed by infusion of WIN55 5 min after ROSC significantly decreased TNFα plasma protein expression at ROSC 4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween N=3, SR141716A+WIN55 N=5. My contribution (a) design of the experiments (b) execution of experimental procedure (c) Analysis of the data.

Figure 54. Plasma IL6. IM Administration of SR141716A before VF+CPR followed by infusion of WIN55 5 min after ROSC significantly decreased IL6 plasma protein expression at ROSC 4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween N=3, SR141716A+WIN55 N=3. My contribution (a) design of the experiments (b) execution of experimental procedure (c) Analysis of the data.
Figure 55. Plasma Troponin I. IM Administration of SR141716A before VF+CPR followed by infusion of WIN55 5 min after ROSC had no effect on cardiac troponin I plasma protein expression at ROSC 4hrs. Mean ± SD, Unpaired t test, $p>0.05$ vs %Tween N=3, SR141716A+WIN55 N=5. My contribution (a) design of the experiments (b) execution of experimental procedure (c) Analysis of the data.

Figure 56. Plasma IL10. IM Administration of SR141716A before VF+CPR followed by infusion of WIN55 5 min after ROSC decreased IL10 plasma protein expression at ROSC 4hrs. Mean ± SD, Unpaired t test, *$p<0.05$ **$p<0.01$ ***$p<0.001$ vs %Tween N=3, SR141716A+WIN55 N=5. My contribution (a) design of the experiments (b) execution of experimental procedure (c) Analysis of the data.
**DISCUSSION**

In the cardiovascular system, CB₂ is present in various cell types (97). Therefore, IM Administration of SR141716A (CB₁ antagonist) before VF+CPR followed by infusion of WIN55 (CB₁ and CB₂ agonist) 5 min after ROSC was used as a treatment group to determine CB₂ agonist response to CA/CPR. HR decreased significantly at ROSC 2hrs and 3hrs while ETCO₂ increased significantly at ROSC 1hr through 4hrs with treatment. MPI also increased significantly at ROSC 4hrs. Our experimental CA/CPR (145, 162, 163) model indicates that TNFα, IL6, and IL10 plasma protein expression is decreased at ROSC 4hrs with SR141716A+WIN55 treatment. Cardiac troponin I and S100A8 protein expression did not change between groups. This could be due to the timing of plasma collection (ROSC 4hrs).
Relative cardiac S100A8 and S100A9 mRNA expression in mice subjected to myocardial IR procedures had peak S100A8/A9 mRNA expression at 6hrs in the heart (132).

CONCLUSION

TNFα, IL6, and IL10 plasma protein expression decreased at ROSC 4hrs with SR141716A+WIN55 treatment. Cardiac troponin I and S100A8 protein expression does not change.

LIMITATIONS

Confirmation of the CB2 receptor as anti-inflammatory still needs to be validated in vivo. There are two different antagonists of CB2 (SR144528(114) and AM630(200)) that can be tested to determine if administration blocks the anti-inflammatory effect of WIN55. Antagonists of CB1 such as AM251 also need to be tested to determine if administration blocks the anti-inflammatory effect of WIN55. Further studies are also needed using more specific CB2 receptor agonists such as HU308 or JWH-133(200).

If we have tissue available after lipidomic analysis from a collaborator-a future study could include immunoblot of the brain and heart for S100A8 and S100A9. Therefore, future studies could look at expression of S100A8 and S100A9 peptides in brain and heart and protein levels in plasma at ROSC 4hrs or with a survival model at 24, 48 and 72hrs. Analysis of S100A8/A9 protein expression with a treatment group of WIN55 would further enhance the mechanism of this pharmacologic tool. Inhibitors of S100A8 and/or S100A9 should also be tested in vivo. The effects of WIN55 should also be tested to determine if they are attenuated by PPARγ antagonist GW9662 (204).
CHAPTER 7: Summary and Future Direction

Accumulating evidence indicates that synthetic or endogenous cannabinoids protect against central nervous system injury by factors including ischemia and reperfusion (200). Brain CB₂ receptors are highly inducible; thus, under some pathological conditions (inflammation), CB₂ expression is quickly enhanced (109). Di Filippo et al. demonstrate that treatment with the synthetic nonselective CB₁/CB₂ receptor agonist WIN55 significantly reduces the extent of myocardial infarct in mice suffering from myocardial IR injury; cardio protection is accompanied by lower myeloperoxidase activity and IL-1β and CXC chemokine ligand levels in injured tissue. This cardioprotective effect is almost abolished by the selective CB₂ antagonist AM630, but it is not affected by the selective CB₁ antagonist AM251 (200) (Fig 42). Although several rodent models have shown promising actions of cannabinoids on the cardiovascular system, we are a long way from seeing these compounds on the market (84). Selective CB₁ receptor antagonists were withdrawn from the market because of increased risk of depression (200).

The effects of WIN55 were investigated initially in our rat model of CA and CPR. WIN55 was selected based on the following reasons: 1) the described hypothermia effect of CB₁ agonist is convincing and well documented, 2) it is highly selective for cannabinoid receptors and interacts negligibly with other neurotransmitter and ion channels (118), 3) it is expressed in thermoregulatory areas of the central nervous system and therefore decreases body temperature via a central mechanism (119), 4) It has been shown to be neuroprotective (120) and 5) It has
been demonstrated in both mice and rats that the CB$_2$ receptor activation effects of WIN55 have significant anti-inflammatory effects (121-123). Our experimental CA/CPR (145, 162, 163) model indicates that local S100A8/A9 protein expression is increased within heart whole tissue lysates after CA and CPR. We then confirmed WIN55 inhibited LPS induced expression of pro-inflammatory cytokines in mouse RAW 264.7 macrophage cells. In vivo TNF$_\alpha$, IL6, and IL10 plasma protein expression decreased at ROSC 4hrs with SR141716A+WIN55 treatment. Li et al recently report S100A8/A9 causes mitochondrial dysfunction via suppression of TLR4/ERK subsequent to mitochondrial complex I inhibition. S100A8/A9 is significantly upregulated during the early reperfusion stage (132). Mitochondria have emerged as central organelles that integrate metabolism and inflammatory responses (79). Therefore, future studies are necessary to determine if WIN55 could be a potential therapeutic to mitigate brain and heart damage after CA and CPR by blocking S100A8/A9 expression. We have determined brain mitochondria are more sensitive to global ischemia compared to heart mitochondria. Additionally, complex I is the most sensitive ETC complex to ischemic injury and its activity determines rate of OXPHOS following CA and RES. Preservation of brain mitochondrial activity and function during CA by inhibition of S100A8/A9 may enhance outcomes and recovery. For this reason, WIN55 could be a pharmacologic tool that preserves complex I activity during CA.

The exact mechanism by which CB$_2$ activation leads to anti-inflammatory effects and possible S100A8/A9 inhibition needs further investigation with macrophage in vitro studies and our experimental CA/CPR (145, 162, 163) model survival studies (Fig 43). Li et al report serum S100A8/A9 levels 1 day post-percutaneous coronary intervention was significantly greater than
other points (132). We could then look at brain and heart mitochondria, local S100A8 histology and protein expression within the brain and heart along with systemic TNFα, IL6, IL10, cardiac troponin, and S100A8 plasma protein expression 24hrs and 48hrs after ROSC.

Figure 58. Pathways of cannabinoid receptor-mediated protection against Ischemia reperfusion injury. Adapted from (82)
Figure 59. Potential WIN55 inhibition of S100A8 and S100A9. Upon forming a heterodimer, S100A8/A9 is able to exert both intracellular and extracellular effects. Intracellularly, S100A8/A9 serves as a regulator of leukocyte transendothelial migration by promoting microtubule polymerization. It also promotes the downregulation of mitochondrial electron transport chain complex I and ATP production. Extracellularly, S100A8/A9 acts as a damage-associated molecular pattern (DAMP) by binding to TLR4 receptors on phagocytes and triggering the production of inflammatory cytokines.
REFERENCES


130


assays.html?ef_id=EAIaIQobChMlkvbF9sHD7QIViaCGCh0f_gEOEAAYASAAEgIy4vD_BwE:G:s&s_kwcid=AL!3652!3!436793334953!p!!g!!bca%20assays&cid=bid_pca_sbu_r01_co_cp1359_pjt0000_bid00000_0se_gaw_nt_pur_con&gclid=EAIaIQobChMlkvbF9sHD7QIViaCGCh0f_gEOEAAYASAAEgIy4vD_BwE.


VITA

Jennifer Leigh Bradley was born on December 5, 1983 in Charleston, West Virginia. She graduated from Saint Albans High School, Saint Albans, West Virginia in 2002. In May 2006, she received her Bachelor of Arts in Biology from Berea College, Berea, Kentucky. In December 2016, she received her Masters of Science in Microbiology and Immunology with a concentration in Molecular Biology and Genetics from Virginia Commonwealth University, Richmond, Virginia. In the fall of 2017, she continued her graduate career at Virginia Commonwealth University, School of Medicine, Department of Microbiology and Immunology with a concentration in Molecular Biology and Genetics.

Education

Virginia Commonwealth University Richmond, Virginia
Doctor of Philosophy in Microbiology and Immunology 2017-present
Concentration: Molecular Biology and Genetics
Graduation Spring 2021 Current GPA 3.673

Virginia Commonwealth University Richmond, Virginia
Master of Science in Microbiology and Immunology 2016
Concentration: Molecular Biology and Genetics

Berea College Berea, Kentucky
Bachelors of Arts in Biology 2006

Research Experience

Virginia Commonwealth University, Richmond, VA June 2016 – Present
Laboratory and Research Manager
Weil Institute of Emergency and Critical Care Research at VCU
Director: Dr. Wanchun Tang
Deputy Directors: Dr. Mary Ann Peberdy and Dr. Joseph Ornato
Research Focus: Cardiopulmonary Resuscitation

- **Research Management**: I have knowledge of the University research rules and policies and the skills necessary for program development and implementation, including developing project budgets and providing guidance in project management. I help the directors with development of plans for studies that include budget, personnel, space, supplies and equipment. I also have the ability to conduct tests, draw conclusions, and record and document findings including statistical analysis (JMP and Prism). I synthesize research data and draft research grant applications and publishable documents. I also maintain the research website and work with the directors to coordinate the Wolf Creek Conference.
• **Clinical Research Experience:** I possess knowledge and experience with human research subject protection (IRB/WIRB) and HIPAA, including CITI Biomedical, Export Controls, Clinical Research Coordinator, Faculty, Staff, and Students, and GCP certification. I also attended the SOM New Coordinator Training-Nuts and Bolts in August 2016.

• **Bench Research:** I directly supervise research staff by providing training, direction, guidance, and evaluation of operating instruments. This includes a total of 6 visiting scholars each year. I was able to perform the Weil Institute’s small animal cardiac arrest model and maintained complex specialized laboratory instruments this past summer. My responsibilities include delegation of project workloads, providing guidance for project management and adhering to University regulations for inspection.

• **Animal Research:** I monitor the care of research animals and act as a liaison with the IACUC office to ensure that all procedures are in compliance with IACUC and University regulations. This includes IACUC submission, husbandry management, animal ordering, controlled substances, and all inspections. I am also a member of the ACUPAC for IACUC.

**Virginia Commonwealth University, Richmond, VA**

February 2014 – June 2016

**Laboratory and Research Specialist II- Laboratory Manager**

**Department of Pediatrics**

Principal Investigators: Dr. Bruce Rubin & Dr. Henry Rozycki

Research Focus: Aerosol therapy, Airway clearance for lung disease and Type I Alveolar Epithelial Cells

• **Laboratory Management:** I provided support and assistance to the Chairman of Pediatrics with the oversight of basic, translational, and clinical research efforts conducted within his laboratory, which required knowledge of the University research rules and policies. I also acted as a liaison with the Associate Administrative Director of Pediatric Research for all budgetary processes and monitoring of the Department Chair’s expenditures. I developed plans and trials for studies that included budget, personnel, space, supplies, and equipment. I also generated budgets for Co-Investigators and Sub-Investigators with other departments. I managed the onboarding of postdoctoral fellows and students for the laboratory and handled travel arrangements and reimbursements for conferences for the PI and lab members. I also scheduled international teleconference calls and planned accordingly for grant and abstract deadlines. My role required excellent customer service skills; the ability to effectively communicate and to work with individuals from diverse backgrounds and to work in a team environment. I was skilled in program development and implementation and established study time lines and communicated with sponsors for study updates. My role required me to determine priorities and work in a fast-paced, deadline driven environment. I developed and maintained systematic ways for filing and archiving all study related documents and supervised and/or performed data processing.
and data analysis. I oversaw quality assurance of data, assisted with the development of
collection methods, and created and revised study materials, forms, and manuals as
needed. I prepared detailed reports for sponsors of experiments, progress reports,
informed consent, etc. This required me to review scientific journals, abstracts, and other
related literature for information concerning experimental procedures and supplemental
support. I also performed troubleshooting on laboratory equipment and acted as the
primary contact for vendors, compliance officers, and sponsoring agencies. I worked with
post-award monitoring grant expenditures, ordering supplies (Pcard, EVA, Banner and
supply center) and organized lab meetings to maintain dialog among co-investigators
regarding progress. I maintained the research website, trained students, and conducted
laboratory tours for elementary to high school-aged children.

- **Statistical Analysis:** I supervised and/or performed data processing, coordinated data
  analysis, and oversaw quality assurance of data. I became proficient in JMP and
  Microsoft Excel.

- **Clinical Research Experience:** I maintained the Rubin laboratory webpage, patient
  registry, and airway sample bank and ensured all were in compliance with IRB/WIRB
  and University regulations. I consented/enrolled research subjects, conducted study
  visits, processed clinical samples, and maintained REDCap databases. My duties required
  experience in clinical trial management, international registries, patient enrollment,
  sputum collection and processing. I possessed knowledge and experience with human
  research subject protection (IRB/WIRB) and HIPAA, including CITI Biomedical, Export
  Controls, Clinical Research Coordinator, Faculty, Staff, and Students, and GCP
certification. I also trained in CERNER, OnCore, MERCK ICH GCP, Adverse
Experience Reporting, and InForm v4.6 for sponsored clinical trials.

- **Bench Research:** I directly supervised research staff and provided training, direction,
  guidance, and evaluation of operating instruments. I operated and maintained complex
  specialized laboratory instruments and was responsible for delegating project workloads
  and providing guidance in project management. I performed Sputum Biophysical
  Analysis (rheology, sputum hydration, and cough clearance), ELLA/ELISAs, RT-PCR,
  DNA/RNA isolation, tissue culture models: submerged and air-liquid interface of NHBE
  and Type I Alveolar Epithelial Cells, western blots, FACS, confocal, and
  immunohistochemistry. I possessed the ability to conduct tests, draw conclusions,
  record, and document findings.

- **Animal Research:** I monitored the care of research animals and acted as a liaison with the
  IACUC office to ensure that all procedures were in compliance with IACUC and
  University regulations. This included IACUC submission, husbandry management,
  animal ordering, controlled substances, and all inspections. I also taught rodent non-
  survival surgery techniques such as tracheostomy and isolation of lungs after
  bronchoalveolar lavage, mouse breeding and colony management, and sputum
  mucociliary transportability analysis on an upper frog palate.
Virginia Commonwealth University, Richmond, VA  
March 2013 – February 2014  
Laboratory and Research Specialist II- Senior Technician  
Department of Pediatrics  
Principal Investigators: Dr. Bruce Rubin & Dr. Henry Rozycki  
Research Focus: Aerosol therapy, Airway clearance for lung disease and Type I Alveolar Epithelial Cells  
- Laboratory Management: I reviewed scientific journals, abstracts, and other related literature for information concerning experimental procedures and supplemental support. I performed troubleshooting on laboratory equipment and assisted the research manager with monitoring grant expenditures, ordering supplies (Pcard, EVA, Banner and supply center) and organizing lab meetings. I also helped maintain the Rubin lab website, trained students, and conducted laboratory tours for elementary to high school-aged children.  
- Statistical Analysis: I became proficient in JMP and Microsoft Excel, which helped with presentation of data during weekly laboratory meetings and preparation of industry reports.  
- Clinical Research Experience: I consented/enrolled research subjects, conducted study visits, processed clinical samples, and maintained REDCap databases.  
- Bench Research: I performed Sputum Biophysical Analysis (rheology, sputum hydration, and cough clearance), ELLA/ELISAs, RT-PCR, DNA/RNA isolation, tissue culture models: submerged and air-liquid interface of NHBE and Type I Alveolar Epithelial Cells, western blots, FACS, confocal, and immunohistochemistry.  
- Animal Research: I taught rodent non-survival surgery techniques such as tracheostomy and isolation of lungs after bronchoalveolar lavage, mouse breeding and colony management, and sputum mucociliary transportability analysis on an upper frog palate.

Virginia Commonwealth University, Richmond, VA  
February 2012 – March 2013  
Laboratory and Research Specialist I- Lab Manager  
Department of Microbiology and Immunology  
Principal Investigator: Dr. Daniel Conrad  
Research Focus: Immunology, cancer biology, and immunotoxicology  
- Laboratory Management: I facilitated the radiation safety inspections and all applicable paperwork involved including monitoring of radioisotope levels and use and disposal of hazardous waste. I also acted as the Chemical Hygiene Officer. I managed laboratory post award grant reconciliation between the Microbiology and Immunology Office, ordered supplies, maintained and performed troubleshooting on all laboratory equipment and supervised graduate students/hourly workers.  
- Bench Research: I observed and assisted with flow cytometry, western blotting, and real time PCR. I also performed ELISAs and collected tissues and specimens for laboratory analysis.
Animal Research: I monitored the care of research animals and acted as a liaison with the IACUC office to ensure that all procedures were in compliance with IACUC and University regulations. I also managed the mouse breeding colony of a myriad of knockout and transgenic strains. I conducted Flexivent procedures: non-survival surgery to investigate the effects of the house dust mite on various transgenic mouse models.

Virginia Commonwealth University, Richmond, VA
Laboratory and Research Specialist I- Laboratory Specialist
Department of Periodontics
Principal Investigator: Dr. Harvey Schenkein
Research Focus: Immunopathology of periodontal disease
  - Bench Research: I developed and modified protocols and carried out research independently- including tissue culture to isolate human blood cells for culture. I ensured sterility, maintained and grew cell lines, and maintained anaerobic bacterial cultures without contamination. I also performed standard immunological assays such as separation of immune cells, prepared solutions, sterilized reagents and apparatus, and disposed of radioisotope equipment.
  - Animal Research: I gained extensive knowledge of breeding techniques and pregnant mouse/pup anatomy.

Office of Laboratory Services, South Charleston, WV
Microbiologist I
  - Performed standardized bacteriologic and serologic examinations along with QC procedures for the state public health laboratory.
  - Carried out primary isolation techniques of microorganisms; prepared media, solutions, and reagents.
  - Operated laboratory equipment and/or scientific instrumentation for use in conducting diagnostic procedures, which included sterilization of apparatus.
  - Compiled and maintained records on the characteristics of the organisms identified.
  - Performed bacterial identification from patient cultures.
  - Operated gen probe (transcription-based amplification system).
  - Serotyped salmonella, shigella, e. coli, and meningitis isolated cultures.
  - Identified parasites using microscopy techniques on patient stool samples.
  - Processed sputum cultures to isolate tuberculosis.
  - Ensured proper immunohistochemistry-monoclonal antibody staining for the detection of rabies virus.
  - Examined animal cranial necropsy for the identification of rabies.
West Virginia State Police, South Charleston, WV
Evidence Technician I
Forensic Laboratory
- Provided for the custody of all evidence submitted by various law enforcement agencies in West Virginia.
- Maintained detailed records and integrity of evidence according to established laws, regulations, and standards.

Publications


Conferences
Society of Critical Care Medicine Annual Congress 2020
Wolf Creek Conference 2017, 2019, 2021
American Association for Respiratory Care Conference 2013

Grants and Scholarships
2020-VCU Staff Senate Integrity Award $500
2020-Graduate School Travel Grant $300
2020-MPG CPC Travel Award $1,500
2019-VCU Graduate School Hibbs/Waller Scholarship $1,000.
2018-MBG CPC Travel Award $180
2018 Fall LabRoots Scholarship $2,000
2017-2017-B Love of Learning Award from Phi Kappa Phi $500
2015-Jennifer Bradley, Mentor: Dr. Bruce Rubin, Mature adipocytes from obese individuals release IL-13, which increases inflammation and induces a goblet cell phenotype in normal human bronchial epithelial (NHBE) cells at air-liquid interface (ALI). Children’s Hospital Foundation Research Fund. $5,000.

Additional Training & Recognition

VCU Training
• Grace E Harris Leadership Institute 2020 class of the HIGHER Ground Women’s Leadership Development Program
• Wright Center Grant Writing Course
• Multiple Manager Training courses from Human Resources
- Multiple Corporate Education Training courses (Leading Effective Teams, Maximizing Productivity and Managing and Leading Change)
- SOM New Clinical Research Coordinator Boot Camp
- Records Management 101

Collaborative Institutional Training Initiative Course:

- Faculty, Staff, and Students
- Biomedical Responsible Conduct of Research
- Good Clinical Practice
- CITI Export Controls
- Clinical Research Coordinator (CRC)

American Association for Laboratory Animal Science:

- Aseptic Technique for Rodent Survival Surgery
- Introduction to Amphibians
- Introduction to Ferrets
- Introduction to Mice
- Introduction to Rabbits
- Introduction to Rats
- Introduction to Swine
- Mouse Breeding Colony Management
- Post-procedure Care of Mice and Rats in Research Minimizing Pain and Distress
- VCU Animal Research Facility Orientation Course
- Working with the VCU IACUC for staff and students

Other

- Write Now Summer Session National Center for Faculty Development & Diversity 2020
- Grantsmanship for Research Professionals 2020
- RAMS Forum 2018, 2019, 2020
- NCURA Sponsored Project Administration Workshop April and September 2019
- Building Inclusive Communities June 2018
- Bioinformatics 102 June 2018
- Writing and Designing NIH Proposals Webinar February 2017
- SBIR Webinar January 2017
- NIH Grantsmanship Workshop January 2017
- VCU Professional Development Certificate Program September 2016 to present
- Virginia Grants Summit September 2016
• Dangerous Goods Shipping

Student spotlight for VCU Graduate School website Fall 2019:
https://graduate.vcu.edu/welcome/graduate-school-news/student-spotlights/student-spotlight---jennifer-bradley/

Member, Society of Critical Care Medicine 2018-present
Member, American Association for the Advancement of Science 2018
Member, The Honor Society of Phi Kappa Phi November 2014-present

Mentorship

• Summer 2020. Mentor Karen Lo. VCU Medical Student Volunteer.
• Summer 2020. Mentor Matthew Olocco. VCU Medical Student Volunteer.
• Summer 2020. Mentor Hunter Hewlett. VCU Medical Student Volunteer.
• Summer 2019. Mentor Liuzhi Zhang. VCU Medical Student Volunteer.
• Summer 2019. Mentor Lazar Jankovic. VCU Medical Student Volunteer.
• Summer 2019. Mentor Helen Mai. VCU Undergraduate Student Volunteer.
• 2018-2019. Mentor Fenglian He, MD, PhD. Weil Institute of Emergency and Critical Care Research Visiting Fellow.
- 2014-2016. Mentor Tomohiro Akaba, MD, PhD. Department of Pediatrics Postdoctoral Scholar.
- 2014-2016. Mentor Kosaku Komiya, MD, PhD. Department of Pediatrics Postdoctoral Scholar.
• 2013-2014. Mentor Shuichi Kawano MD, PhD. Department of Pediatrics Postdoctoral Scholar.

Service
Graduate Student Rep, SOM Teaching Awards Selection Committee  Summer 2020 and 2019
Volunteer Judge, Virginia Junior Sciences and Humanities Symposium (JSHS)  March 2020
Volunteer, Medical Reserve Corps  September 2008-Present
Volunteer, Emergency Department at MCV  Spring and Summer 2013
Mentor, Tutor of Education and Living Skills  August 2002-May 2006
Volunteer, Health Clinic in Ayacucho, Peru  Summer 2004